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ABSTRACT 
 
Whitney P. Caron:  The Mononuclear Phagocyte System as a Phenotypic Probe for 
Nanoparticle Pharmacokinetics and Pharmacodynamics in Preclinical and Clinical Systems 
Development of a Phenotypic Probe to Individualize Nanoparticle Therapy 
Under the direction of: William C. Zamboni 
 
 
 Nanoparticles, or carrier-mediated agents are unique drug delivery platforms that 
provide numerous advantages, such as greater solubility, duration of exposure, and delivery 
to the site of action over their small molecule counterparts. However, there is substantial 
variability in systemic clearance and distribution, tumor delivery, and pharmacologic effects 
of these agents. This work explores some of the factors that affect the pharmacokinetics and 
pharmacodynamics of nanoparticle agents in preclinical models and patients. The ultimate 
goal of this work was to determine whether nanoparticle therapy could be individualized in 
patients based on some of these factors. 
 The primary biologic focus was to measure the function of circulating cells in the 
blood known to play a role in the clearance of nanoparticles. It was determined that the 
function of monocytes and dendritic cells, as measured by phagocytosis and the production 
of reactive oxygen species (ROS) could serve as a phenotypic probe in patients. A 
phenotypic probe is a test that can be administered to a patient as a potential indicator of a 
drug’s pharmacokinetics and pharmacodynamics, which can then be used to individualize 
therapy. This work uses patients with recurrent epithelial ovarian cancer receiving the 
nanoparticle PEGylated liposomal doxorubicin (PLD; Doxil) as part of their standard of care. 
This work shows an association between cell function and the clearance of PLD for both 
phagocytosis (R2= 0.43, P= 0.04) and production of ROS (R2= 0.61, P= 0.008). This is an 
encouraging finding for patients in light of the high variability seen with nanoparticle agent 
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pharmacokinetics and pharmacodynamics. With more than 250 nanoparticles in late 
preclinical or early clinical development, the issue of addressing variability and 
individualizing therapy will be of the utmost importance. Therefore, this work has the 
potential to be applied to many other nanoparticles and disease states in the future.  
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CHAPTER I 
 
INTRODUCTION1 
 
Nanoparticle Anticancer Agents 
Major advances in nanoparticle or carrier-mediated agents have revolutionized drug 
delivery capabilities over the past decade. While providing numerous advantages, such as 
greater solubility, duration of exposure, and delivery to the site of action over their small 
molecule counterparts, there is substantial variability in systemic clearance and distribution, 
tumor delivery, and pharmacologic effects of these agents. This work explores some of the 
factors that affect the pharmacokinetics and pharmacodynamics of nanoparticle agents in 
preclinical models and patients. The ultimate goal of this work was to determine whether 
nanoparticle therapy could be individualized in patients based on some of these factors. 
The number of available nanoparticle-based drug systems has seen exponential 
growth in the past decade. In 2006 alone, nearly 130 nanotechnology-based products were 
estimated to be undergoing the drug development process worldwide (1) While the number of 
agents used clinically is still limited, the plethora that are emerging as potential therapeutic 
agents warrants the need for detailed studies of their unique pharmacology and mechanisms 
of action in humans. In this introduction, the factors that affect the pharmacokinetics (PK) 
and pharmacodynamics (PD) of anticancer carrier mediated agents in patients are discussed 
and this ultimately leads to our central hypothesis and Specific Aims. 
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  Caron WP, Song G, Kumar P, Rawal S, Zamboni WC. Interpatient pharmacokinetic and pharmacodynamic 
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Nanoparticle Formulations 
 
Particle Classifications. The primary types of carrier-mediated anticancer (CMA) 
agents are nanoparticles, nanosomes, which are nanoparticle-sized liposomes, and conjugated 
agents (2-5). These terms, particularly CMA, nanoparticles, and liposomes are used 
interchangeably and will be throughout this document. Nanosomes are further subdivided 
into stabilized and nonstabilized or conventional nanosomes. Nanospheres and dendrimers 
are subclasses of nanoparticles. Conjugated agents consist of polymer-linked and PEGylated 
agents. There are also >100 nanosomal, nanoparticle, and conjugated anticancer agents that 
are in preclinical and clinical development. Newer generations of carrier-mediated agents 
containing two anticancer agents within a single nanosome or nanoparticle and antibody-
targeted nanosomes and nanoparticles that may improve selective cytotoxicity are in 
preclinical and clinical development (6-8). In addition, nanosomes, nanospheres, conjugates, 
and dendrimers offer a unique method to provide tumor-selective delivery of anticancer 
agents to tumors (8). 
 
Pharmacokinetic Characterization. The disposition of CMA is dependent upon the 
carrier and not the parent drug until the drug gets released (7). The nomenclature used to 
describe carrier-mediated pharmacokinetics includes: encapsulated (the drug within or bound 
to the carrier), released (active drug that gets released from the carrier), and sum total 
(encapsulated drug plus released drug) (8, 9). After the drug is released from its carrier it is 
pharmacologically active and subject to the same routes of metabolism and clearance as the 
noncarrier form of the drug (8). In theory, the PK disposition of the drug after it is released 
from the carrier should be the same as after administration of the small molecule or standard 
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formulations. Thus, the pharmacology and PK of CMA are complex and comprehensive 
analytical studies must be performed in order to assess the disposition of encapsulated or 
released forms of the drug in plasma and tumor (10). Considerable interpatient variability 
exists in the PK and PD of CMA, and while the exact factors are unclear, it is hypothesized 
that the mononuclear phagocyte system (MPS) (or reticuloendothelial system; RES) plays a 
key role (11). MPS and RES are synonymous although MPS is the preferred terminology. 
The PK of liposomal encapsulated drug and released drug is very different, and 
compared with conventional small molecule anticancer agents, the PK variability in 
liposomal formulations is often much greater (8). Interindividual variability in drug exposure, 
represented by area under the concentration versus time curve (AUC), of encapsulated drug 
can be 20 to 100-fold. Factors with the potential to affect CMA PK include CMA-associated 
physical characteristics and host-associated characteristics, such as age and gender (12). 
Perhaps the greatest influence on the PK variability of CMA, however, is the MPS. Figure 1 
illustrates the unique clearance mechanisms associated with CMA as compared with 
conventional small molecules (12, 13).  
 
Mononuclear Phagocyte System (MPS) 
 
The MPS is defined as a group of cells having the ability to ingest large numbers of 
particles (13). These cells, comprised of monocytes and dendritic cells (MO/DC) circulating 
in the blood, fixed macrophages of various connective tissues, Kupffer cells in the liver, and 
macrophages in the lymph nodes, bone marrow, and spleen, serve as a potential CL pathway 
for NPs (13-15). 
           Once a nanoparticle enters the bloodstream it encounters an intricate network of 
plasma proteins and immune cells (15). The interaction and subsequent effects of 
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nanoparticle therapeutics on the immune system have not been fully elucidated, but 
presently, are generally placed into one of two categories: 1) responses to nanoparticles that 
are specifically modified to stimulate the immune system (e.g. vaccine carriers), and 2) 
undesirable interactions and/or side-effects (16). In this work, the focus will be on the latter, 
which may have profound clinical implications. 
           Nanoparticle uptake by immune cells can occur in circulating monocytes, platelets, 
leukocytes, and dendritic cells (DC) of the bloodstream (15, 16). In addition, nanoparticles 
can be taken up in tissues by phagocytes, such as Kupffer cells in the liver, DC in the lymph 
nodes, macrophages, and B cells in the spleen (15).  Figure 2 illustrates the interaction and 
clearance of CMA with these immune cells, collectively termed the MPS. Uptake 
mechanisms may occur through different pathways and can often be facilitated by the 
adsorption of opsonins to the nanoparticle surface (15).   
           Many nanoparticles have been developed for the purpose of evading rapid clearance 
from the bloodstream and thereby extending systemic circulation time (15). While this allows 
for a greater probability of nanoparticle delivery to a target site, an increase in circulation 
time results in a proportional increase of duration of contact with components of the immune 
system (15). CMA PK and PD differences seen in patients can be attributed to many different 
variables, particularly components of the MPS. 
 
Bidirectional Interaction Between Nanoparticles and the MPS 
           A phase I study investigated the relationship between the disposition of the carrier-
mediated agent S-CKD602 (PEGylated liposomal CKD-602, a camptothecin analogue) and 
changes in monocytes and absolute neutrophil count (ANC) (17). As a control, changes in 
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monocytes and ANC were also evaluated after patients received non-liposomal CKD-602 in 
a phase I study of refractory solid tumors and a phase II study of refractory ovarian cancer 
(17). The % decrease in ANC and monocytes from baseline to nadir from the blood of all 
patients administered S-CKD602 on cycle 1 was measured. The mean ± standard deviation 
(SD) day of ANC and monocyte nadir was 15.3 ± 5.0 and 8.6 ± 3.3 days, respectively (p = 
0.008). The mean ± SD % decrease in ANC and monocytes at nadir was 42 ± 30 and 58 ± 
34%, respectively (p= 0.001). The ratio of percent decrease in monocytes to ANC at the nadir 
was 2.1 ± 2.0. The % decrease in ANC and monocytes at nadir in the blood of patients was 
also assessed after administration of nonliposomal CKD-602. The mean ± SD day of ANC 
and monocyte nadir after administration of nonliposomal CKD-602 was 14.0 ± 3.5 and 9.2 ± 
3.0 days, respectively (p > 0.05). After administration, the % decrease in ANC and 
monocytes were 86 ± 11 and 87 ± 12%, respectively (p> 0.05). The ratio of percent decrease 
in monocytes to ANC was 1.0 ± 0.2. 
           The same study selected a pharmacodynamic endpoint of bone marrow suppression in 
order to investigate a potential relationship between exposure of encapsulated and released 
CKD-602 with monocytopenia and neutropenia. The exposure (area under the curve; AUC) 
of encapsulated CKD-602 and percent decrease in monocytes at nadir showed a relationship 
among patients less than 60 years of age (R2= 0.75). There was no relationship between 
released CKD-602 AUC and % decrease in monocytes at nadir, nor between encapsulated or 
released CKD-602 AUC and % decrease in ANC at nadir. The results of this first study 
evaluating the PK and PD relationships between a liposomal anticancer agent and immune 
cells in patients suggests that monocytes are more sensitive to S-CKD602 compared with 
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neutrophils. The increased sensitivity also appears to be related to the liposomal formulation, 
and not the released drug from the liposome or the small molecule formulation. 
           Some of the significant variability in the pharmacokinetic dispositions of CMA versus 
small molecules was found to be related to linear and nonlinear (saturable) clearance of S-
CKD602 in patients (18). The incidence of linear or nonlinear clearance was found to be 
associated with the dose of S-CKD602 administered (18). At doses from 0.1 to 1.1 mg/m2, 
the S-CKD602 sum total and encapsulated CKD-602 plasma concentrations were best 
described using a model with linear clearance in all the patients (n= 33) (19). At doses of 1.7–
2.5 mg/m2, the S-CKD602 sum total and encapsulated CKD-602 plasma concentrations were 
best described using a model with linear (n= 2) and nonlinear (n= 10) clearances (19). Four of 
the six patients treated at the maximum tolerable dose of 2.1 mg/m2 had nonlinear clearance 
of sum-total and encapsulated CKD-602. The AUCs of sum total and encapsulated CKD-
602, normalized by dose, were significantly greater in patients with nonlinear clearance than 
in those with linear clearance (p< 0.05), as shown in Tables 1 and 2. The observation of non-
linear PK at higher doses of CMA coincides with the hypothesis of MPS uptake in particle 
clearance and its subsequent saturation. However, there was significant interpatient 
variability in CL with patients exhibiting linear and nonlinear CL at the same dose.  
It has also been shown that monocyte function, as assessed by phagocytosis and 
oxidative burst can predict the PK of PEGylated liposomal doxorubicin (Doxil) in patients 
with refractory ovarian cancer (20). A direct linear relationship was seen between monocyte 
phagocytosis at baseline (prior to the start of chemotherapy) (R2= 0.43) and the CL of Doxil, 
as well as oxidative burst activity in monocytes at baseline (R2= 0.61) and the CL of Doxil in 
6 patients (20). Moreover, this study found that the phagocytic capacity of monocytes in 
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blood declines over time in the first cycle of chemotherapy, potentially indicating that they 
are saturated with Doxil particles (20). This study is described fully in Chapter 3.  
Enhanced Permeability and Retention (EPR) Effect and Delivery of CMA to Tumors 
 
Major advances in understanding of tumor biology have led to the discovery of 
targeted agents delivering drugs to the desirable site while minimizing exposure in normal 
tissues and associated adverse effects.  While conventional drugs encounter numerous 
obstacles en route to their target, CMA can take the advantage of tumor’s leaky vasculature 
to extravasate into tissue via the enhanced permeability and retention effect (EPR) (21, 22). 
Furthermore, the poor lymphatic drainage in tumors leads to accumulation of the CMA for 
prolonged duration, allowing them to release the drug in tumor cells over time. Passive 
targeting exploits the classic features of tumor biology (leaky vasculature and dysfunctional 
lymphatic drainage) in order to increase exposure of CMA in the tumor. Although passive 
targeting via the EPR effect has been a key concept in delivering CMA to the tumor, it does 
not ensure uniform delivery to all the regions of tumor (23). Furthermore, not all tumors 
exhibit EPR effect and the permeability of vessels may not be the same across a single tumor 
(24).  
Active targeting may overcome these limitations when the CMA bind to specific cells 
in tumor using surface-attached ligands capable of recognizing and binding to cells of 
interest (25). Relative to normal cells, tumor cells have certain overexpressed surface 
receptors or antigens that maximize the specificity of binding of targeted agents. One such 
strategy for the tumor-targeted drug delivery is the development of immunoliposomes. For 
example, anti-HER2-targeted liposomal doxorubicin was associated with higher efficacy 
compared to its non-targeted counterpart in a breast cancer model (26). In a recent study, 
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PEGylated poly lactide-co-glycolide acid (PLGA) docetaxel immunonanocarriers targeted to 
HER2 positive breast cancer cells were shown to have higher cytotoxicity than the non-
targeted PLGA nanoparticles (27). While antibody-mediated targeting has been the method of 
choice, other targeting strategies, using nucleic acids, carbohydrates, peptides, aptamers, 
vitamins etc, are also being evaluated (24). 
Several preclinical studies support extensive tumor delivery and prolonged exposure 
of PEGylated liposomes in tumors (8). The development of PEGylated liposomes, which 
contain lipid conjugated to polyethylene glycol (PEG) was based on a theory that their 
incorporation into nanosomes would evade the immune system and help prolong duration of 
exposure (12). This is consistent with higher anti-tumor activity of Doxil in preclinical 
models compared with doxorubicin and with clinical activity in patients with refractory 
ovarian cancer and Kaposi sarcoma (28).  In studies comparing the disposition of PEGylated 
liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human 
melanoma xenografts, S-CKD602 provided pharmacokinetic advantages in plasma, tumor, 
and tumor ECF at 1/30th of the dose. This was consistent with the improved antitumor 
efficacy of S-CKD602 in preclinical studies (29). 
Tumor exposure and antitumor activity of liposomal anticancer agents was found to 
be related to the presence of the MPS in tumors (29). This was demonstrated in mice bearing 
SKOV-3 human ovarian and A375 human melanoma xenografts (29). The ratio of S-
CKD602 in tumor to plasma was 1.7-fold higher in mice bearing SKOV-3 compared with 
A375 (29).  The ratio of released CKD-602 to S-CKD602 in tumor was 2-fold higher in mice 
bearing SKOV-3 compared with A375 (29). The staining of MPS cells was 4.5-fold higher in 
SKOV-3 compared with A375 (p< 0.0001) (29).  In addition, SKOV-3 was 4-fold more 
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sensitive to S-CKD602 compared with A375 (29).  The increased tumor delivery and release 
of CKD-602 from S-CKD602 in SKOV-3 ovarian compared with A375 melanoma 
xenografts was consistent with the increased staining of MPS cells in SKOV-3 suggesting 
that variability in the MPS may affect the tumor disposition and activity of nanosomal 
anticancer agents (29).  
In another study using murine colon tumor xenografts, the sum total (encapsulated 
and released) tumor platinum exposure was four-fold higher with PEGylated liposomal 
cisplatin (SPI-077) compared with nonliposomal cisplatin (30). However, since the sum total 
platinum concentrations were measured in tumor extracts, it is unclear whether the platinum 
measured was encapsulated or released. It is important to note that the released fraction can 
be either protein bound or unbound. In spite of four-fold higher exposure associated with 
SPI-77 compared with cisplatin, this did not translate into anti-tumor activity in clinical 
trials. Consistent with that lack of antitumor effects in patients, a subsequent study showed 
that SPI-077 entered tumors but did not release platinum into tumor extracellular fluid and 
formed significantly less Pt-DNA adducts than cisplatin (10). Therefore, it is imperative that 
the disposition of both encapsulated and released versions of liposomes be evaluated in 
tumors of patients for successful development of CMA. While concentrations of SPI-077 and 
cisplatin in tumor ECF represent an exposure in the vicinity of the malignancy, they may not 
represent a true measure of efficacy, as cytotoxicity is dependent upon the formation of 
platinum (Pt)-DNA adducts (10). Microdialysis has been used to study the relationship 
between unbound Pt in tumor ECF and total Pt in tumor homogenates, as well as formation 
of Pt-DNA adducts in a group of female C57BL/6 bearing B15 melanoma flank tumors (10). 
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Administration of SPI-077 resulted in Pt tumor concentrations that were 2.2- to 5-fold higher 
than after administration of cisplatin (10).  
 
Alteration of PD Toxicity by CMA 
It has been found that CMAs modify the toxicity profiles of small-molecule drugs. In 
the case of anthracyclines (e.g., doxorubicin), cardiotoxicity related to the cumulative dose 
has traditionally limited their clinical use (31). Preclinical studies have demonstrated that 
liposomal carrier–mediated anthracyclines reduce the incidence and severity of cumulative 
dose-related cardiomyopathy while preserving the antitumor activity of the small-molecule 
drug (31). In addition, direct comparisons between Doxil or Caelyx and conventional 
doxorubicin in clinical studies showed comparable efficacy but significantly lower risk of 
cardiotoxicity with the use of the PEGylated liposomal formulations of doxorubicin (31). In 
addition, histologic examination of cardiac biopsies from patients who received cumulative 
doses of Doxil from 440 to 840 mg/m2, with no prior exposure to anthracyclines, revealed 
significantly less cardiac toxicity than in matched doxorubicin controls (P < 0.001) (32). This 
effect on improving the cardiotoxicity profile of doxorubicin may be attributable to the 
alteration in tissue distribution associated with liposomal formulations (10, 28, 30, 33). 
However, surprisingly, the administration of a CMA may also result in the development of 
additional toxicities (34-36). For example, the most common adverse events associated with 
the use of Doxil are hand–foot syndrome (also known as palmar–plantar erythrodysesthesia) 
and stomatitis, neither of which has been reported with the use of conventional doxorubicin. 
The exact mechanism associated with these toxicities is unknown, but they have been shown 
to be schedule- and dose-dependent. They can also be dose-limiting in some patients (35). 
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XMT-1001 is a carrier-mediated conjugate polymer formulation of camptothecin. The 
clinical development of camptothecin was halted despite the demonstration of its antitumor 
activity in phase I trials because it was associated with severe hemorrhagic cystitis. However, 
the results from clinical studies have shown that XMT-1001 is not associated with this 
toxicity ((9). This effect of avoiding severe bladder toxicity appears to be specific to XMT-
1001; clinical results with alternative camptothecin-polymer conjugates show that they are 
associated with cystitis (37, 38). The proposed hypothesis to explain this differential effect 
with regard to toxicity is that other conjugate formulations release camptothecin directly into 
urine, whereas XMT-1001 does not (39) 
LE-SN38 is a liposomal encapsulated formulation of SN-38, the active metabolite of 
the prodrug irinotecan. Severe diarrhea (that may be dose-limiting and potentially fatal) has 
been shown to occur as both an early-onset (<24 h, 43–51%; grade 3/4: 7–22%) and a late-
onset (≥24 h, 83–88%; grade 3/4: 14–31%) toxicity with the use of irinotecan (40). In a phase 
I dose-escalation study of LE-SN38 infused intravenously over a duration of 90 min every 21 
days in patients with advanced cancer (n = 75), diarrhea was reported as being generally mild 
and self-limiting, and no late-onset diarrhea was reported by any patient (41). In addition, in a 
single-arm, open-label phase II study in patients with metastatic colorectal cancer (n = 30) 
receiving LE-SN38 35 mg/m2 intravenously over a duration of 90 min every 21 days, none of 
the patients reported grade 3/4 diarrhea toxicity (42). The lower incidence and severity of 
diarrhea were seen despite high plasma SN-38 exposures (41, 42).  
Lipoplatin is a liposomal formulation of cisplatin. Cisplatin administration is 
frequently associated with renal insufficiency and tubular dysfunction (43). In preclinical 
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studies, mice and rats injected with cisplatin developed renal insufficiency with clear 
evidence of tubular damage, but those injected with the same dose of lipoplatin were almost 
completely free of kidney injury. Moreover, the maximum levels of total Pt in rat kidneys 
after intraperitoneal bolus injection of cisplatin or lipoplatin at equivalent doses were similar 
(~10 µg Pt/g kidney), but the steady-state accumulation of total Pt in the kidney was five 
times higher after cisplatin than after lipoplatin. This is a potential mechanism to explain the 
low renal toxicity of lipoplatin (44). In a phase I dose-escalation study in patients receiving 
lipoplatin infused over a period of 8 h every 14 days at doses of 25–125 mg/m2 (n = 27), no 
patient showed signs of nephrotoxicity as measured by renal function tests (blood urea, 
serum creatinine, and creatinine CL) before and after treatment (45). In addition, in a phase 
III study of patients (n = 229) randomized to either lipoplatin 200 mg/m2 plus paclitaxel 135 
mg/m2 or cisplatin 75 mg/ m2 plus paclitaxel 135 mg/m2 every 2 weeks, those in the 
lipoplatin treatment arm demonstrated significantly lower toxicities, including 
nephrotoxicity, leukopenia, nausea/vomiting, and asthenia than those in the cisplatin arm (P 
≤ 0.001, 0.017, 0.042, 0.019, respectively) (45).  
Cofactors that Contribute to Nanoparticle PK Variability 
Age. PK studies of Doxil administered in three phase I and II studies in patients with 
solid tumors (n = 22 and 12, respectively) and in patients with AIDS-related Kaposi's 
sarcoma (n = 36) were performed. The mean ± SD CL values of sum total Doxil in patients 
<60 and ≥60 years old were 54.6 ± 28.5 and 23.3 ± 10.8 ml/h/m2, respectively (P < 0.0001) 
(46). This age cutoff was based on previous studies of PEGylated liposomal anticancer agents 
using these categories (47). Age and gender influences have also been evaluated 
retrospectively in PK studies of Doxil (n = 70), PEGylated liposomal irinotecan (IHL-305) (n 
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= 39), and S-CKD602 (n = 45) in patients with solid tumors and Kaposi's sarcoma (48). Male 
patients <60 years of age had a 2.2-fold higher CL of Doxil and a 2.1-fold higher CL of S-
CKD602 as compared with male patients ≥60 years of age (48). However, age did not appear 
to affect the CL of Doxil and S-CKD602 in female patients. This could be attributable, in 
part, to the fact that many of the female patients in these studies were older women with 
refractory ovarian cancer, in contrast to patients with Kaposi's sarcoma, who have been 
shown to have lower mean ages and body weight and increased CLs of Doxil relative to 
patients with solid tumors (P < 0.001 each) (46). Consequently, the age-related effects may be 
altered in certain patient populations. Also, in both male and female patients, age did not 
appear to affect the CL of IHL-305(48).  
Age-related effects on the PK of some PEGylated liposomal agents have been 
reported. In a phase I and PK study of S-CKD602 in patients with advanced malignancies, 
there was a statistically significant (P = 0.01) relationship between higher age and higher S-
CKD-602 AUC/dose (19). In addition, patients ≥60 years of age had a 2.7-fold higher 
exposure of S-CKD602 as compared with patients <60 years of age (P = 0.02), as shown in 
Figure 3A and 3B (19). 
 Age-related effects on the PD of CMAs have also been reported. Age-related effects 
in the relationship between neutropenia and monocytopenia after administration of S-
CKD602 were tested by evaluating the percentages of decrease and rates of decrease of ANC 
and monocytes in patients <60 and ≥60 years of age (17). After administration of S-CKD602, 
the mean ± SD percentages of decrease in ANC and monocytes at nadir in patients <60 years 
of age were 43 ± 31 and 73 ± 26%, respectively (P = 0.003) (17). The mean ± SD ratio of the 
percentage decrease in monocytes to that in ANC in patients <60 years of age was 2.5 ± 2.6 
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(17). In patients ≥60 years of age, the mean ± SD percentages of decrease in ANC and 
monocytes at nadir were 41 ± 31 and 45 ± 36%, respectively (P = 0.5) (17). The ratio of the 
percentage decrease in monocytes to that in ANC was 1.7 ± 1.3 (17). On the basis of the 
overall exposure to encapsulated S-CKD602, it appears that there is a greater reduction in 
monocytes at the nadir in patients <60 years of age as compared with those ≥60 years of age 
(17). The latter study concluded that monocytes are more sensitive to S-CKD602 than 
neutrophils are, that increased sensitivity is related to the encapsulated liposomal formulation 
of CKD-602, and that age impacts this interaction (17). These findings are consistent with the 
age-related effects on the CL of PEGylated liposomes. 
 To evaluate how monocytes affect the PK of S-CKD602, the inter-relationships 
among the percentage decrease in monocytes, the CL of the encapsulated drug, and the 
release of CKD-602 from its carrier in plasma were evaluated. In all patients (R2 = 0.51), 
those <60 years of age (R2 = 0.54), and those ≥60 years of age (R2 = 0.49), there were linear 
relationships between the percentage decrease in monocytes and both CL of encapsulated 
CKD-602 and release of CKD-602, as shown in Figure 4A and 4B, respectively. 
Gender. Gender was also found to be one of the many factors contributing the PK 
and PD variability of CMAs. The effect of gender on CL of Doxil (n = 70), IHL-305 (n = 
39), and S-CKD602 (n = 45), with and without stratification by age, was evaluated in PK 
studies conducted as part of phase I and phase II studies (46). Female patients had a 2.4-fold 
lower overall CL of Doxil (P < 0.001), a 1.4-fold lower overall CL of IHL-305 (P = 0.068), 
and a 1.3-fold lower overall CL of S-CKD602 (P = 0.67) as compared with male patients 
(46). Female patients also had lower CLs of Doxil, S-CKD602, and IHL-305 when stratified 
by age (<60 and ≥60 years old) (46). In addition, an evaluation of the plasma PK disposition 
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of liposomal topotecan and S-CKD602 in male and female rats found the CL of liposomal 
topotecan and S-CKD602 to be 1.2-fold (P = 0.14) and 1.4-fold (P = 0.009) lower, 
respectively, in female rats than in male rats (49). The basis for the gender-related differences 
in the PK and PD of CMAs is unclear. It has been hypothesized that some of the differences 
may be attributed to the effects of sex hormones such as testosterone and estrogen on 
immune cell function (46). 
Body Composition. PK studies of Doxil were conducted as part of three phase I and 
II studies in patients with solid tumors (34 patients) and in patients with AIDS-related 
Kaposi's sarcoma (36 patients) (46). Body surface area and body mass index were evaluated 
as potential factors affecting the CL of Doxil (46). The linear regression coefficient between 
body surface area and Doxil CL (ml/h) during cycle 1 was R2 = 0.25. Body surface area 
contributed to a relative reduction of 8.6% in the variability of CL (46). There was no 
significant relationship between Doxil CL during cycle 1 and body composition as measured 
by actual body weight/ideal body weight or body mass index (R2 = 0.22 and 0.13, 
respectively) (46). However, it was reported that patients with an actual body weight/ideal 
body weight ratio <1.35 have a higher plasma exposure of S-CKD602 as compared with 
patients with an actual body weight/ideal body weight ratio ≥1.35 (P = 0.02), perhaps 
because of a smaller volume of distribution (19). Although there was no relationship between 
body composition and Doxil CL, this could be attributable to the small sample size and/or to 
the inclusion of patients with very high actual body weight/ideal body weight ratios (46). 
Additional data collection through CMA clinical pharmacology studies is warranted to 
explore the potential relationship between body composition and nanoparticle CL. 
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Presence of Liver Tumors. In a phase I PK study evaluating encapsulated and 
released CKD-602, 45 patients were enrolled; 26 of these had various types of liver tumor(s) 
and 19 did not have liver tumors (50). Linear and nonlinear PK models were constructed for 
encapsulated CKD-602, and it was determined that liver tumor was a significant covariate for 
maximum velocity (Vmax). The inclusion of liver tumor as a covariate in the model decreased 
the coefficient of variation in Vmax by 29% (50). The variability in CL of encapsulated S-
CKD602 in patients with and without liver tumors is shown in Figure 5 (50). The interpatient 
variability in S-CKD602 PK disposition could possibly be explained by the presence of 
metastatic liver tumors, given that the Vmax in patients with these tumors is 1.5-fold higher 
than in patients without liver tumors (50). These data suggest that patients with liver tumors 
may have 35% lower plasma exposure of encapsulated CKD-602, leaving them at risk for 
low response. This finding is interesting because, historically, most studies have shown a 
decrease in CL of small-molecule drugs in patients with liver tumors as compared with those 
without liver tumors (51, 52) 
Summary of Impact on PK/PD of CMAs 
 There is a growing body of evidence to indicate that various factors such as age, body 
composition, gender, and cellular function contribute to the variability of PK/PD of CMAs in 
patients. These factors may all operate at the level of the MPS and have the ability to increase 
or decrease MPS function. This subsequently translates to alterations in CMA CL and 
exposure. Ultimately this process may lead to either reduced or greater efficacy and/or 
toxicity. The problem with this clinical manifestation lies in the fact that the target response 
must balance efficacy and toxicity, and the ideal CMA exposure needs to be elucidated 
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through further research. The interplay of MPS function and its effect on PK and, ultimately, 
on PD are illustrated in Figure 6. 
 There are a multitude of properties of CMAs that differ from those of the active 
small-molecule drugs they contain. These differences lead to significant variability in the PK 
and PD of carrier-mediated drugs. It has been shown that physical properties, the MPS, the 
presence of tumors in the liver, EPRs, drug–drug interactions, age, and gender all contribute 
in varying degrees to the PK disposition and PD end points of CMAs in patients. 
 Given the unique and highly variable CL mechanisms of CMAs, it is important that 
these agents continue to be extensively evaluated during all phases of preclinical and clinical 
development. Areas of research that can aid in an understanding of how these agents should 
be used and how we may predict their actions in patients include pharmacogenomics, cellular 
function (probing the MPS), more sensitive and accurate analytical PK methods, and 
identification of the optimal preclinical (animal and in vitro) models. 
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Table 1. Exposure to Sum Total and Encapsulated CKD-602 is Significantly Greater in Patients 
with Nonlinear Clearance than in Those with Linear Clearance. 
 
AUC, area under the concentration-time curve; CL, clearance; t1/2, elimination half-life 
Table 1. Compartmental pharmacokinetic parameters of sum total CKD-602 after S-CKD602 administration in 
patients with linear and nonlinear dispositions.at1/2is the terminal half-life. bEstimates are from six patients. 
cEstimates are from 10 patients. dEstimates are from two patients each in the <60 and >60 years age groups. e 
The sum total CKD-602 AUC normalized by dose in patients with linear disposition was significantly greater in 
patients > 60 years than in those <60 years of age (p= 0.03; CI 5.6-78.0).f  The sum total CKD-602 AUC 
normalized by dose was significantly greater in patients with nonlinear disposition as compared with patients 
with linear disposition from both age groups (p= 0.01). 
  Linear Pharmacokinetic Disposition Nonlinear 
Pharmacokinetic 
Disposition 
Parameter Unit Age < 60 Mean ± 
SD 
(range) n= 14 
Age > 60 Mean ± SD 
(range) n= 22 
All Ages 
Mean ± SD (range) 
n= 9 
k10 1/h 0.5 ± 0.7 (0.005-
2.4) 
0.2 ± 0.3 (0.02-0.7) - 
t1/2a h  13.9 ± 6.9 (6.2-
31.4) 
17.2 ± 8.8 (7.6-39.7) 22.8 ± 7.9 (7.4-34.4) 
V L/m2 2.9 ± 1.4 (1.2-5.4) 3.0 ± 2.1 (0.72-9.87) 2.1 ± 0.7 (1.4-3.9) 
CL L/h/m2 1.3 ± 1.4 (0.008-
3.9) 
0.81 ± 1.25 (0.03-3.6) - 
k12 1/h 1.4 ± 1.8b (0.1-4.3) 0.5 ± 0.5c (0.009-
1.68) 
- 
k21 1/h 0.3 ± 0.5b  (0.05-
1.3) 
0.3 ± 0.4c  (0.002-1.4) - 
k13d 1/h 0.4 
0.5 
0.1 
0.5 
- 
k31d 1/h 0.002 
0.005 
0.8 
0.5 
- 
Km ng/mL - - 995 ± 759 (30-2,987) 
Vmax ng/h - - 35 ± 22 (8-73) 
Sum total 
AUC/Dose 
(ng/mL*h)/(mg/m2) 3,941 ± 5,283 
(240-18,917)e,f 
9,644 ± 10,876 (279-
36,800) 
25,887 ± 11,023 
(3,504-40,892) 
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Table 2. The observation of Non-Linear PK at Higher Doses of CMA Coincides with the 
Hypothesis of MPS Uptake in Particle Clearance and its Subsequent Saturation. 
 
Table 2.aThe k12 in patients <60 and >60 years of age were estimated from two patients and one patient, 
respectively. bThe k21 in patients <60 and >60 years of age were estimated from two patients and one patient, 
respectively. cThe encapsulated CKD-602 AUC normalized by dose in patients with linear disposition was 
significantly greater in patients >60 years of age than in patients <60 years of age (p= 0.02; CI= 9.7-89.4). dThe 
encapsulated CKD-602 AUC normalized by dose was significantly greater in patients with nonlinear disposition 
than in patients with linear disposition from both age groups (p= 0.01).  
 
  Linear Pharmacokinetic Disposition Nonlinear 
Pharmacokinetic 
Disposition 
Parameter Unit Age < 60 Mean 
± SD 
(range) n= 14 
Age > 60 Mean ± 
SD 
(range) n= 22 
All Ages 
Mean ± SD (range) 
n= 9 
k
10
 1/h 0.25 ± 0.43 
(0.03-1.29) 
0.13 ± 0.27 (0.01-
0.96) 
- 
V L/m
2
 4.54 ± 2.65 
(1.86-9.27) 
2.78 ± 1.65 (1.26-
7.25) 
1.68 ± 0.17 (1.49-
1.86) 
CL L/h/m
2
 1.88 ± 3.65 
(0.10-10.62) 
0.76 ± 2.05 (0.02-
7.25) 
- 
k
12
a 1/h 0.13 
0.51 
0.37 - 
k
21
b 1/h 0.17 
0.52 
0.38 - 
K
m
 ng/mL - - 1,282 ± 1,356 
(160-4,163) 
V
max
 ng/h - - 38.9 ± 41.4 
(1.93-106.8) 
k
release
 1/h 0.015 ± 0.011 
(0.004-0.033) 
- - 
Encapsulated 
AUC/Dose 
(ng/mL*h)/(mg/m
2
) 4,723 ± 6,716 
(53-23,184)c,d 
12,778 ± 12,228 
(90-41,318) 
28,410 ± 11,464 
(12,309-44,224) 
Released 
AUC/Dose 
(ng/mL*h)/(mg/m
2
) 88 ± 66 (2-203) 173  ± 293 (15-
1,359) 
206 ± 217 (60-734) 
Ratio of 
released AUC 
to encapsulated 
AUC 
 0.26 ± 0.60 
(0.002-2.1) 
0.07 ± 0.16 
(0.003-0.53) 
0.007 ± 0.004 
(0.003-0.017) 
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Figure Legends 
 
 
Figure 1. Small molecule anticancer agents undergo a standard route of metabolism and 
elimination, including enterohepatic recycling and removal through the kidney. Carrier 
mediated agents, however, which are engulfed by phagocytes, are contained primarily in 
compartments such as the spleen, liver, and peripheral blood mononuclear cells. 
 
Figure 2. When non-stabilized liposomal agents were first tested, they were found to only 
minimally increase the circulation time of the small molecule agent encapsulated within the 
carrier (rapid clearance). However, stabilization with polyethylene glycol, (PEG) has helped 
to reduce uptake and CL of CMA by MPS (slower clearance). While the clearance of 
PEGylated liposomes are slower than non-PEGylated liposomes, both are phagocytized by 
peripheral blood mononuclear cells (PBMC), phagocytes of the liver and spleen. Greater 
tumor exposure is seen after administration of PEGylated liposomes, which in part due to the 
enhanced permeability and retention (EPR) effect and possibly, the MPS in tumors. 
 
Figure 3. (A, B) The relationship between age and the area under the curve (AUC)/dose for 
encapsulated CKD-602 after S-CKD602. The AUC/dose values for encapsulated CKD-602 
in patients <60 and ≥60 years of age are presented. The values for individual patients are 
represented by open circles. The mean and median values of AUC/dose for each group are 
represented by filled triangles and filled squares, respectively. The mean ± SD values of 
AUC/dose for sum total CKD-602 in patients <60 and ≥60 years of age were 3,941 ± 5,283 
and 9,644 ± 10,876 (ng/ml)/(mg/m2), respectively (P = 0.02; clearance = 9.7, 89.4  ml/h/m2). 
(C) The relationship between age and clearance (CL) of encapsulated doxorubicin (Doxil) in 
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patients <60 and ≥60 years of age, with filled squares representing the mean clearance in the 
respective cohort. 
 
Figure 4. (A) The relationship between percentage decrease in monocytes at the nadir and 
the clearance of encapsulated CKD-602 in plasma. Linear regression (R2 = 0.57) is 
represented by the solid line. (B) The relationship between percentage decrease in monocytes 
at the nadir and the area under the curve of released CKD-602 in monocytes at the nadir in 
each patient was calculated using the respective patient’s serial monocyte count (obtained 
during cycle 1) and applying the standard formula: ((prevalue – nadir)/prevalue) × 100. 
 
Figure 5. Variability in encapsulated CKD-602 CL in patients with and without tumors in 
their liver. The mean difference in clearance between the two groups was statistically 
significant, p= 0.02. 
 
Figure 6. There is a growing body of evidence to indicate that factors such as age, body 
composition, gender, cellular function, and concomitant medications contribute to the 
variability in the pharmacokinetics (PK) and pharmacodynamics of carrier-mediated agents 
(CMAs) in patients. All these factors operate at the level of the mononuclear phagocyte 
system (MPS) and have the ability to up- or downregulate its function, thereby potentially 
altering CMA clearance and area under the curve (AUC)/exposure. This ultimately leads to 
either reduced or greater efficacy and/or toxicity. The predicament of this clinical 
manifestation lies in the fact that the target response must balance efficacy and toxicity, and 
this ideal CMA exposure needs to be elucidated through further research. 
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Figure 1. The Clearance Mechanisms of Small Molecule and Carrier Mediated Agents 
Designed to Deliver Chemotherapeutics. 
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Figure 2. Clearance of PEGylated and Non-PEGylated Nanoparticles/Liposomes via the 
Mononuclear Phagocyte System (MPS). 
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Figure 3. Age-Dependent Effects on CMA PK 
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Figure 4. Effect of Monocytes on CMA Clearance (CL) 
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Figure 5. Presence of Liver Tumors Alters CL of Encapsulated CKD-602 
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Figure 6. The Interplay of CMA and the MPS and its Effect on PK and PD 
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Specific Aims 
 
 
I. To evaluate the function of monocytes and dendritic cells (MO/DC) of the 
MPS as part of in vivo and ex vivo systems as phenotypic probes for the PK 
and PD of PLD in women with recurrent ovarian cancer. 
Hypothesis. The development of phenotypic probes will assist cancer patients by 
predicting NP efficacy [overall survival (OS) and/or progression free survival 
(PFS)], toxicity [e.g. HFS or palmar plantar erythrodysethesia (PPE)], and 
determining the proper dose to administer prior to the initiation of therapy.  
II. To evaluate the function of MO/DC and tissue macrophages of the MPS in 
animal models of NP efficacy and toxicology.  
Hypothesis A.  The cellular function of tissue macrophages (liver, spleen, and 
tumor) in preclinical models and their interaction with NPs will be comparable to 
the function and particle uptake of circulating MO/DC in the blood. 
Hypothesis B.  The ability to measure the effect that NPs have on cellular function 
in blood and tissues of animals will elucidate the most appropriate animal model 
to be used in PK and toxicology testing.  
III. To profile the interaction between nanoparticle agents and the MPS via an ex 
vivo high throughput screening platform (HTSP).  
Hypothesis A.  Development of a high throughput screening platform can 
characterize and profile the interaction of NP agents with the MPS in blood 
samples and this information can be used to optimize the drug development of NP 
agents for the treatment of cancer and other diseases.  
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Hypothesis B.  When there is a low interaction between NPs and the MPS, the 
agent could likely be used as a chemotherapy agent, and conversely, when there is 
a strong interaction, it could serve as a potential immunotherapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
 30 
CHAPTER II 
 
ALLOMETRIC SCALING AND INTERSPECIES DIFFERENCES IN 
NANOPARTICLE PK AND PD2 
 
Introduction 
 
 The pharmacokinetic (PK) disposition of PEGylated liposomal formulations of 
CKD602 (S-CKD602), doxorubicin (Doxil®), and cisplatin (SPI-077), have been evaluated 
in preclinical models and in patients (29, 53, 54). The ability to extrapolate animal data to 
predict PK parameters in humans is an essential step in the drug development process (53). 
The generalizability of preclinical data to predict the safety and efficacy of new molecular 
entities in humans is often viewed with skepticism, but it is believed to provide reasonably 
well-fit data when selecting the appropriate PK parameters (55). Allometric scaling is one 
method commonly employed to predict various PK parameters in humans from animal data 
(53). This method is used to select a first dose to be administered to humans in clinical phase 
I trials during drug development (53).  
Rats and dogs are the two most commonly selected preclinical models used for Good 
Laboratory Practices (GLP) toxicology and toxicokinetic studies of small molecules and 
nanoparticles. From an evolutionary standpoint, all mammals are quite similar, having 
originated from a common ancestor, but they differ in term(56)s of their environmental 
adaptations (55). Since humans share similarities in anatomy, physiology, and biochemistry 
with other mammals, the most significant difference is their size (55). The standard approach 
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to allometric scaling is using the power-log relationship between pharmacokinetic processes 
and body weight among mammals (53, 55, 57)  
Presented here, is the use of allometric scaling to predict PK parameters, namely 
clearance (CL) of PEGylated liposomal anticancer drugs in humans. With historical data 
suggesting that the clearance mechanisms of PEGylated liposomes is in large part due to the 
mononuclear phagocyte system (MPS), we explored variables in addition to standard species 
body weight. Liver weight, spleen weight, monocyte count, spleen blood flow, and liver 
blood flow, all factors associated with the MPS were allometrically scaled to determine if 
parameters other than body weight best predicts the disposition of this unique class of 
anticancer agents.  
The main objective of the study was to determine whether allometric scaling of 
PEGylated liposomal anticancer drugs was possible. Subsequently¸ we sought to determine 
the best physiological variables and animal models to use from the available data in order to 
predict PK disposition of PEGylated liposomes in humans. We hypothesized that some of the 
MPS-associated factors would demonstrate a stronger relationship with PK parameters using 
allometric scaling than would standard body weight alone. 
 
Materials and Methods 
 
Pharmacokinetics. Concentration versus time data for S-CKD602, Doxil®, and SPI-
077 was imported into WinNonlin Version 5.2.1 (Pharsight Corp., Mountain View, CA) and 
a non-compartmental analysis was used to obtain PK parameters. The preclinical and clinical 
studies of each agent and the methods used to measure drug concentrations are detailed 
below. Sum total (encapsulated and released) concentrations were measured for each 
PEGylated liposomal anticancer agent. These agents are >95% encapsulated in stock and 
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plasma, and therefore the sum total PK of drug is primarily encapsulated drug (54, 58, 59). 
The encapsulated drug form is unique to liposomal and nanoparticle agents and thus was of 
primary interest to our study.  
 
S-CKD602 Studies. S-CKD602 was administered at 1 mg/kg as a single IV bolus to 
SCID mice (n = 3 males, n = 3 females). Plasma samples were taken at 5 minutes, 15 
minutes, and 0.5, 1, 2, 4, 7, 16, 24, 48, and 72 hours after administration. S-CKD602 was 
administered at 0.6 mg/kg as a single IV bolus dose via a tail vein in Sprague-Dawley rats (n 
= 3 males, n = 3 females). Plasma samples were obtained immediately after giving the dose, 
and at 4, 8, 24, 48, and 72 hours after administration. S-CKD602 was administered at 0.07 
mg/kg IV over 30 minutes to Beagle dogs (n = 3 males, n = 3 females). Plasma samples were 
taken at the end of infusion, and 1, 2, 4, 8, 24, 48, and 72 hours after administration. As part 
of phase I studies, S-CKD602 was administered at 1.7, 2.1, and 2.5 mg/m2, as an IV infusion 
over 1 hour. Plasma samples were collected at the end of infusion, and at 2, 4, 8, 24, 72, 96, 
192, and 360 hours after administration. Liquid chromatography-mass spectrometry (LC/MS) 
was used to quantify plasma sum total (encapsulated and released) CKD-602 concentrations, 
which had a lower limit of quantitation (LLOQ) of 1 ng/mL (29). 
 
Doxil®. Studies Doxil® was administered at 6 mg/kg as a single IV bolus dose via a 
tail vein in SCID mice (n=3 males, n = 3 females). Plasma samples were obtained at 5 
minutes, and 2, 4, 8, 24, 48, 72, and 96 hours after administration. Doxil® was administered 
at 1 mg/kg as a single IV bolus dose via a tail vein in Sprague-Dawley rats (n = 3 males, n = 
3 females). Plasma samples were obtained at 0.5, 2, 4, 8, 24, 48, and 72 hours after 
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administration. Doxil® was administered at 1.5 mg/kg IV over 30 minutes to Beagle dogs (n 
= 3 males, n = 3 females). Plasma sampling times were 0.05, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 
72, and 96 hours after the dose. As part of phase I studies, Doxil® was administered at 40, 
50, and 60 mg/m2 as an IV infusion over 1 hour. Plasma samples were drawn at 0.33, 1, 3, 5, 
7, 28, 48, 72, 96, 336, 505, and 670 hours after the end of the infusion. High-performance 
liquid chromatography (HPLC) with fluorescence was used to measure sum total doxorubicin 
with an LLOQ of 10 ng/mL (53, 60). 
 
SPI-077. Studies SPI-077 was administered at 10 mg/kg as a single IV bolus via a tail 
vein in SCID mice (n = 3 males, 3 females). Plasma samples were obtained at 2, 24, 48, 96, 
and 144 hours after administration. SPI-077 was administered at 5 mg/kg as a single IV bolus 
dose via a tail vein in Sprague-Dawley rats (n = 3 males, 3 females). Plasma samples were 
obtained at 0.15, 2, 6, 24, 48, 72, 96, and 168 hours after administration. SPI-077 was 
administered at 7.5 mg/kg IV over 30 minutes was to Beagle dogs (n = 3 males, 3 females). 
Plasma samples were taken at 0.2, 0.6, 2, 4, 24, 72, 168, and 336 hours after the dose. As part 
of phase I studies, SPI-077 was administered at 80, 120, and 200 mg/m2, as an IV infusion 
over 1 hour. Plasma samples were taken at 5, 6, 8, 24, 48, 72, 168, and 336 hours after 
administration. Flameless atomic absorption spectroscopy (FAAS) was used to measure 
plasma concentrations of sum total cisplatin with an LLOQ of 0.125 uM (55, 57).  
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Allometric Scaling History and Equations 
 Allometric scaling is based on the power function as the body weight from several 
different species is plotted against a pharmacokinetic parameter of interest on a log-log scale 
(55). The power function is written as (61): 
Y = aWb                         (1) 
 Where Y is the parameter of interest, W is body weight (kg), and a and b are the 
coefficient and exponent of the allometric equation, respectively (61). a and b are empirically 
derived, and the exponent b represents the slope of the regression line when plotted on log-
log coordinates (62, 63).  
Studies indicate that drug clearance cannot always be well predicted by only relying 
on the use of equation 1 (64, 65). Therefore, several different approaches have emerged in 
order to improve the predictive capabilities of allometry for drug clearance. One concept is 
based on neoteny, where clearance is predicted from species body weight and Maximum 
Life-span Potential (MLP) (66).  
CL = a (W)b       (2)   
           MLP 
 
Where 8.18 x 105 is the MLP value, in hours in humans. MLP was first calculated in years in 
the equation described by Sacher (67): 
MLP (years) = 185.4(BW)0.636(W)-0.225       (3) 
Where BW represents brain weight and W body weight, and both are given in kilograms.  
 Another approach to allometric scaling are the species invariant time methods (61-67). 
These methods are detailed in Appendix I. The final equations used for this method include: 
The Dedrick Time Equivalent Model, where the Y axis is normalized by dividing plasma 
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concentrations by dose (mg/kg) and body weight W (kg), and 0.25 represents a constant for 
the conversion from chronological to physiological time on the X axis.  
 The Elementary Dedrick Plot which is expressed as: 
Y-axis = Concentration    (4) 
        Dose/W 
 
X-axis = Time      (5) 
     W1-b 
Where b is the exponent of clearance. 
The Complex Dedrick Plot is expressed as (61): 
Y-axis = Concentration    (6) 
        Dose/Wc 
 
X-axis = Time      (7) 
     Wc-b 
 
Where b and c are exponents of clearance and volume, respectively.  
 Standard allometry, MLP, Dedrick Time Equivalent Model, Elementary Dedrick Plot, 
and Complex Dedrick Plot, were all used to determine whether PEGylated liposomal CL 
could be scaled between mice, rats, dogs, and humans. CL was scaled using the following 
physiological variables: body weight, spleen weight, liver weight, kidney weight, liver blood 
flow, spleen blood flow, and total monocyte count. Table 3 summarizes the values used for 
these factors in mice, rats, dogs, and humans. Table 4 provides the average (SD) of CL, Vd 
and half-life for S-CKD602, Doxil®, and SPI-077 in mice, rats, and dogs, and humans.  
 The last analysis was to test the accuracy and generalizability of the allometric 
scaling equations. PK data from phase I studies of S-CKD602, Doxil®, and SPI-077 was 
imported into WinNonlin in order to determine the CL of these agents in patients. The CL 
values for humans were labeled as “observed” values. “Scaled” values of CL were 
determined by adding human BW, liver weight, spleen weight, kidney weight, liver blood 
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flow, spleen blood flow, or total monocyte count into the respective allometric equations 
determined previously. These two values were compared for each agent and % difference 
was calculated. 
 
Results 
 
 Standard Allometric Scaling. Measured concentration versus time profiles of mice, 
rats, dogs, and humans for S-CKD602, Doxil®, and SPI-077 are shown in Figure 7A, 7B, 
and 7C, respectively. After CL was obtained for each agent and each species, standard 
allometric scaling was performed using body weight (68). Figure 8A shows that clearance 
was correlated with body weight across all agents [S-CKD602 (R2 = 0.974), Doxil® (R2 = 
0.977), and SPI-077 (R2 = 0.892)].  Using the standard allometric equation, the MPS-
associated variables (liver weight, spleen weight, spleen blood flow, liver blood flow, and 
monocyte count) were assessed as variables for correlation. Spleen blood flow and monocyte 
count are shown in Figure 8B and 8C. All of the MPS probes showed correlation with the 
three PEGylated liposomes with respect to clearance. R2 regression values using the MPS 
probes are summarized in Table 5. S-CKD602 and Doxil® had the strongest correlation 
across all physiological variables and demonstrated similar trends compared to each other. 
SPI-077 differed from S-CKD602 and Doxil® when scaling CL among the different MPS 
variables, with a weaker relationship than the other two agents. Kidney weight, when scaled 
with clearance across all three agents had R2 values of 0.986, 0.964, and 0.766, for S-
CKD602, Doxil®, and SPI-077, respectively. The strongest correlation coefficients across all 
agents were observed when CL was scaled by total monocyte count with R2 values of 0.954, 
0.989, and 0.933, for S-CKD602, Doxil®, and SPI-077, respectively.  
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(69) Allometric scaling using the Maximum Life-Span Potential (MLP) Method for CL 
was also evaluated using the same MPS variables. As would be expected, a relationship was 
observed when CL was multiplied by the MLP in hours of a mouse, rat, or dog and plotted 
against their body weight. As CL was highly correlated with body weight and MPS-
associated variables previously, adding MLP improved the observed trend. This was 
particularly noticeable for SPI-077, the agent with the lowest correlation using standard 
allometric scaling. The correlation for SPI-077 improved by an average of 0.05.  
 Species Invariant Time Models. The next scaling method used was the Dedrick 
Time Equivalent Model. The concentration versus time profiles of the three PEGylated 
liposomes did not converge among species when scaling in this manner. The lack of 
superimposability was also seen when substituting liver weight, spleen weight, and total 
monocyte count for body weight. (data not shown).One trend that was observed in the Time 
Equivalent Model was that after normalizing both axes on the concentration versus time 
profile, dogs had the fastest clearance and consequently the lowest exposure (AUC) for all 
three agents.  
 Complex Dedrick Plots for S-CKD602, Doxil®, and SPI-077 were also constructed. 
The use of liver weight, spleen weight, or total monocyte count did not improve the fit of the 
data when compared to body weight (data not shown). 
 The Elementary Dedrick Plot scaled models for S-CKD602, Doxil®, and SPI-077 
showed no superimposability among any of the species or between a single species and 
humans, for any of the PEGylated liposomes. The same lack of superimposability was seen 
in the Complex Dedrick Plot, the Elementary Dedrick and, Time Equivalent models when 
normalizing by a physiological variable other than body weight (data not shown).  
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 Lastly, we sought to explore whether standard allometric equations could be used to 
predict CL in humans. Table 6 summarizes the results of using the standard allometric 
equation for body weight or monocyte count to predict CL in patients. The most accurate 
predictor of PEGylated liposomal CL in humans occurred after inputting monocyte count in 
humnas into the allometric equation. A 390%, 696%, and 262% difference existed between 
predicted (scaled) and actual CL for S-CKD60, Doxil®, and SPI-077, respectively. 
 
  
Discussion 
 
 Choosing the appropriate starting dose of a new molecular entity to administer in a 
phase I clinical trial is a significant issue and concern. Allometric scaling and 
physiologically-based pharmacokinetic modeling (PBPK) are the most commonly used and 
recommended strategies for accomplishing this goal (69). While using allometric scaling to 
predict CL of drugs in humans is often found to be ineffective, it is currently one of only a 
few methods available to estimate starting dose in phase I clinical trials, and is widely used 
and accepted by the pharmaceutical industry and the Food and Drug Administration (FDA) 
for this indication (70). However, its use has not been widely evaluated for liposomal and 
nanoparticle agents. Thus, we performed the first study to evaluate the application of 
allometric scaling for PEGylated liposomal and nanoparticle anticancer drugs.  
 Standard PK models do not always predict disposition of PEGylated liposomes and 
nanoparticle anticancer agents. This could be due to the fact that these carriers have unique 
PK characteristics that are different than their small molecule counterparts. This study 
represents allometric scaling of liposomal formulations and not the small molecule drug (i.e., 
camptothecin, anthracycline, or platinum) encapsulated in the liposome. All agents tested in 
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this study have a >95% encapsulation of the active drug in the liposome in plasma (29, 53, 55, 
57, 60). In addition, our laboratory assays found a >2-log difference between encapsulated 
and released drug concentrations in plasma, indicating that the PK disposition presented in 
this study is attributed to the encapsulated (carrier) form.  
 The main reason allometric scaling often does not work for drugs is due to major 
differences in drug metabolism across species (71). Species possess many different 
cytochrome P450 enzymes and gut microflora that are involved in the metabolism of 
xenobiotics (71). An example of this concept is given by phenylbutazone, which has a half-
life of 3 hours in rabbits, 6 hours in rats, guinea pigs, and dogs, and 3 days in humans. 
Phenylbutazone CL does not allometrically scale with body weight because each animal 
metabolizes the drug differently. Due to metabolic differences, this phenomenon is seen with 
many different drugs. Another reason for allometric scaling failure, is that it is generally 
recommended that at least three orders of magnitude be covered in terms of species weights 
for scaling (71). However, using a broader range may be more ideal (72). In our study, the 
three preclinical species (mice, rats, dogs) have body weights spanning over three orders of 
magnitude; however, additional species would have provided more data points and possibly a 
greater correlation between preclinical models and patients (72). 
 This study evaluated parameters other than body weight which may be used to more 
accurately scale the disposition of PEGylated liposomes in animals and humans. We 
demonstrated that clearance of three PEGylated liposomal anticancer drugs was consistently 
related to several different physiological variables. The relationship between body weight or 
MPS-associated variables and drug clearance was not consistent among the three PEGylated 
liposomal agents. However, the parameter that showed the strongest relationship to liposomal 
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clearance across all agents was total monocyte count. S-CKD602 had the highest R2 values 
for all of the physiological variables that were evaluated. 
 While the three agents chosen for study are all members of the same class of drugs, 
subtle differences in their composition could have contributed to scaling differences. All 
agents are reported to have a hydrodynamic diameter of ~100 nm and contain a lipid bilayer 
with an outer coating of PEG; however, the amount of lipids and cholesterol differ in content 
and concentration. Also, an average concentration was taken for each group of species which 
was then used to calculate a clearance. This may not adequately address the inter and 
intrapatient variability seen in the PK of PEGylated liposomes. A strategy that could be 
employed in the future could be a population analysis such as the two-stage or fully 
population approach instead of the naïve pooled data approach used here. Additionally, PK 
parameters of PEGylated liposomes may be different between species and this could make 
their behavior in humans difficult to predict. SPI-077 and Doxil® appear to exhibit nonlinear 
profiles in humans, and this could undoubtedly lead to inability to accurately predict CL from 
preclinical data. Our studies also do not incorporate fraction unbound (fu) values between 
humans and animals, which has been shown to improve predictions, particularly when human 
observed values are lower than the predicted values (73).  
The addition of MLP to the standard allometric equation increased the correlation of 
CL when using MPS related factors such as liver weight, spleen weight, and monocyte count 
compared to standard allometric methods. Therefore, MPS probes may be reasonable 
predictors of PEGylated liposome PK; however, there may be considerable differences across 
species in terms of MPS activity or function. These species differences could be blunted by 
the addition of MLP because the lifespan of dogs is notably longer than rats or mice, and thus 
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the best-fit trend line becomes more linear. It is difficult to discern whether the linearity was 
achieved due to MPS or MLP factors, particularly when the MPS has not been extensively 
evaluated in a wide variety of animals. MLP is often used for the correlation of 
pharmacodynamic measures, that is, the relationship between drug exposure and effects 
and/or toxicity. MLP is also used for a measurement of effects over a lifetime rather than 
parameters measured over an abbreviated period of time.  While the MLP method showed 
improvement in scaling abilities for PK parameters and physiological variables, it could also 
have significant contributions in terms of pharmacodynamic properties. These studies can be 
performed after the MPS function is more fully characterized in animals and humans as 
related to nanoparticle clearance.  
 Substituting the different physiological variables for body weight into the Dedrick 
Plots created similar results where the profiles were not superimposable. This is most likely 
due to the fact that using body weight to scale produced nearly identical results in terms of 
R2 values as the other, MPS-associated physiological variables. When PK parameters and 
physiological variables of a similar fit were tested, it was not possible to witness further 
improvement in species invariant time models. As discussed by Tang and Mayersohn, a log-
log transformation of the allometric power function will minimize deviations from a 
regression line (73).  When a prediction confidence interval is generated from this data and 
then transformed back to a linear scale, the interval becomes too wide to confidently predict 
PK parameters (73).  
 This study was not able to determine the ideal preclinical model from which to scale 
PEGylated liposomal anticancer drugs. While only three animals were tested, dogs were a 
consistent outlier from a best-
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variables. When data was fit to the Time Equivalent Model, dogs appeared to clear the 
PEGylated liposomes faster than all other species, including humans. While the MPS has not 
been evaluated comprehensively in animal models, it is known that canines exhibit marked 
differences in red blood cells compared to other species (73, 74).  For example, immune-
mediated hemolytic anemia (IMHA) is a frequently diagnosed immune disorder in dogs (75). 
There is currently not enough information to postulate whether this is the reason for 
differences observed with dogs compared to other animals and patients. Thus, there is a need 
to explore the underlying mechanism associated with these differences. As clinical phase I 
studies use data from the most sensitive preclinical species to determine the starting dose in a 
phase I clinical trial, dogs may not be an appropriate model for toxicology and PK studies of 
liposomal and nanoparticle agents.   
 These findings add to previous work which demonstrated that MPS factors are 
involved in the clearance of PEGylated liposomes (75). As part of a phase I clinical study, 
patients were administered S-CKD602. There was a significant decrease in monocyte count 
but not in ANC. The increased monocytopenia compared to neutropenia was not seen after 
administration of nonliposomal CKD-602 (NL-CKD602). An age-dependent effect was also 
observed, with a larger percent decrease in monocytes and ANC in patients <60 years of age 
treated with S-CKD602 (76). It was determined that monocytes were more sensitive to S-
CKD602 compared to neutrophils, and the increased sensitivity is related to the liposomal 
formulation, not CKD-602 (76). The results suggested that monocytes engulf S-CKD602 
which causes the release of CKD-602 from the liposome and toxicity to the monocytes, and 
the effect is most prominent in patients <60 (76). 
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 This work also adds to recent studies that apply PBPK models to nanoparticles. It was 
found that adjustments are needed in order to build suitable PBPK models for nanoparticles, 
which behave much differently than their small molecule counterparts.  
 
Conclusions 
 
 This study determined that a general relationship exists between body weight and 
MPS-associated variables such as liver weight, spleen weight, liver blood flow, spleen blood 
flow, or monocyte count and clearance of PEGylated liposomal anticancer agents in animals. 
The CL of PEGylated liposomes scale in mice, rats, and dogs; however, allometric scaling 
does not predict CL in humans using body weight. We found that using monocyte count may 
be a better physiological variable for the allometric scaling of PEGylated liposomes in 
animals and humans. Species Invariant Time Models did not show superimposibility among 
any agent or species concentration versus time profile. This could be due to formulation 
differences among the PEGylated liposomes or species variability in clearance mechanisms. 
It is clear that selection of species, physiological variables, and PEGylated liposome used in 
this study all contribute in varying degrees to the results.  
 There is preliminary evidence that factors associated with the MPS, such as monocyte 
count may improve the prediction of CL in humans. It will be essential to further test this 
hypothesis by evaluating whether the CL of PEGylated liposomes can be scaled across 
species using other measurements of the MPS, such as monocyte and macrophage activity or 
function.  In addition, future studies need to apply the analyses described in this study to 
other liposomal and nanoparticle agents that are in development.  
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Appendix I includes allometric scaling plots of all MPS-associated variables, including those 
scaled by the MLP method. In addition, standard concentration versus time profiles and the 
Elementary, Complex, and Time Equivalent Dedrick Models are also available within the 
supplement. 
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Table 3. Physiological Variables Used for Mice, Rats, Dogs, and Humans. 
 
Physiological Variable      Mouse            Rat                   Dog                 Human 
Body weight (kg) 0.02 (0.001) 0.24 (0.044)  11.6 (1.14) 69.9 (9.73) 
MLP (h) 35040 41172 175200 818000 
Liver Weight (kg) 0.00175 0.00549 0.2632 1.6705 
Spleen Weight (kg) 0.0001 0.0003 0.0216 0.169 
Kidney Weight (kg) 0.00032 0.001095 0.044 0.286 
Liver Blood Flow 
(mL/min) 
1.8 8.28 247.2 1346.4 
Spleen Blood Flow 
(mL/min) 
0.09 0.378 20 71.5 
Monocytes (total count) 11,232 191,100 474,000,000 1,200,000,000 
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Table 4. Average (SD) Noncompartmental Pharmacokinetic Parameters in Four 
Species 
 
PEGylated 
Liposome 
         Mouse            Rat      Dog             Human 
S-CKD602 CL 
(mL/h) 
       0.09 (0.005) 0.45 (0.08) 44.1 (11.9) 72.5 (24.3) 
S-CKD602 Vd 
(mL) 
S-CKD602 t ½ (h) 
Doxil® CL (mL/h)                                                                  
     1.09 (0.02) 
    8.18 (2.1) 
0.0406 (0.0159) 
8.93 (1.21) 
12.9 (1.75) 
0.406 (0.159) 
819.0 (254.0) 
13.1 (3.01) 
13.1 (2.99) 
3190 (1510.0) 
42.2 (19.8) 
20.7 (8.25) 
Doxil® Vd (mL)      1.21 (0.04)     10.6 (1.4)    605.0 (12.6)        1960 (617.0) 
Doxil® t ½ (h) 
SPI-077 CL (mL/h) 
       22.1 (1.25) 
2.03E-0 (1.19E-
05) 
21.3 (2.91) 
0.213 (0.159) 
28.6 (5.4) 
3.49 (2.24) 
          65.5 (19.6) 
          79.4 (12.1) 
SPI-077 Vd (mL) 9.0E-04 (1.0E-
04) 
8.06 (0.51) 259.0 (26.4) 15300 (659.0) 
SPI-077 t ½ (h)      24.3 (12.1)      26.2 (6.8) 51.4 (8.47) 132.4 (17.1) 
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Table 5. Summary of Average (SD) R2 Regression Values, Coefficients, and Exponents 
Using the Standard Allometric Equation. 
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Table 6. Scaled and Observed CL for S-CKD602, Doxil®, and SPI-077 
with % Difference, in Humans. 
 
 Body Weight Monocyte Count 
 S-CKD602  Doxil®   SPI-077  S-CKD602  Doxil®    SPI-077 
Observed 
mean CL (SD) 
in a Phase I 
Clinical Study 
(mL/h) 
 
72.5 (24.3) 20.7 
(8.25) 
79.4 
(12.1) 
72.5 (24.3)  20.7    
(8.25) 
79.4 
(12.1) 
Predicted CL 
from Scaling 
(mL/h) 
 
355 165 290    57.7 59.3 17.5 
% Difference 390 696 262    -20.4 186 -78.2 
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Figure Legends 
 
Figure 7. Measured mean concentration versus time profiles in mice, rats, dogs, and humans 
for S-CKD602, Doxil, and SPI-077. 
Figure 8. Comparison of S-CKD602, Doxil, and SPI-077 clearance (from left to right) in 
mice, rats, dogs, and humans, by allometric scaling of body weight, spleen blood flow, and 
total monocyte count. Human data is included in allometric graphs to demonstrate the general 
behavior of liposomes across all species, however human data was not included in the 
regression which was used to predict behavior of liposomal PK in humans from preclinical 
species. 
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Figure 7. Pharmacokinetic Profiles of PEGylated Liposomal Anticancer Agents. 
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Figure 8. Allometric Scaling of PEGylated Liposomal Anticancer Agents by Body 
Weight, Spleen Blood Flow, and Monocyte Count.  
 
 
0.000001 
0.00001 
0.0001 
0.001 
0.01 
0.1 
1 
10 
100 
1000 
10000 
0.01 0.1 1 10 100 
0.000001 
0.00001 
0.0001 
0.001 
0.01 
0.1 
1 
10 
100 
1000 
0.01 0.1 1 10 100 
0.000001 
0.00001 
0.0001 
0.001 
0.01 
0.1 
1 
10 
100 
1000 
1.00E+01 1.00E+03 1.00E+05 1.00E+07 1.00E+09 1.00E+11 
C
le
ar
an
ce
 (m
L/
h)
 
Body Weight 
Spleen Blood Flow 
Total Monocyte Count 
Physiologic Scaling Parameter 
(kg) 
(Count) 
(mL/min) 
	  
	  
 52 
CHAPTER III 
 
A REVIEW OF NANOPARTICLE VS. SMALL MOLECULE  
PHASE I CLINICAL STUDIES3  
 
Introduction 
Preclinical trials of anticancer drugs require a rodent and non-rodent model for 
toxicokinetic (TK) and toxicologic studies (77).  The non-rodent model most commonly 
selected is a canine (77). The toxicologic and TK data is used to determine the starting dose 
in phase I trials based on one-tenth of the rodent LD10 (lethal dose for 10% of population 
tested) or one-third of the dose associated with the dose-limiting toxicity (DLT; side effects 
of a drug or other treatment are serious enough to prevent an increase in dose or level of that 
treatment) in dogs (77, 78). The starting dose in the first in human phase I study of anticancer 
agents is then based on dose in the most sensitive species (77). 
The most predictive animal model for toxicology and pharmacology studies of NPs is 
unclear (79, 80). The CL of PEGylated liposomes in preclinical species has been assessed 
through allometric scaling (81).   PK studies were performed at the maximum tolerated dose 
(MTD) of PEGylated liposomal doxorubicin (Doxil; PLD), CKD-602 (S-CKD602 and 
cisplatin (SPI-077) in mice, rats, and dogs, and as part of phase I studies in patients with 
refractory solid tumors (78, 81). Dogs had the fastest CL of the three different PEGylated 
liposomes evaluated when compared to mice, rats, and humans (81). As these studies were 
performed at the MTD, dogs also had the lowest exposure associated with toxicity, which 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
3 Caron WP, Morgan KP, Zamboni BA, Zamboni WC. A Review of study designs and outcomes of phase I 
clinical studies of nanoparticle agents compared with small molecule anticancer agents. Clinical Cancer 
Research. 2013 Jun 15; 19(12):3309-15. 
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suggests that dogs may not be appropriate models for NP toxicology or pharmacology studies 
(81).   
It has been observed that the starting doses in phase I trials for NPs are considerably 
lower and more dose escalations are required to reach the first signs of toxicity and 
eventually DLT compared with SM (10, 15).  
When developing therapeutic agents that are associated with potential high costs and adverse 
events it is critical to optimize the preclinical and clinical study designs of these drugs. 
Therefore, the objective of the current study was to conduct a review of clinical phase I trials 
of NPs and equivalent SM to evaluate whether significant differences existed in study design, 
progression, and outcomes between NPs and SM. NPs comprises carrier-mediated platforms 
of anticancer agents, including liposomes and conjugates which contain an active SM, while 
SM includes cytotoxics and any non-nano anticancer agent excluding targeted therapies. 
 
Methods 
 
Study Design. We evaluated differences in how phase I studies of NP and SM were 
designed and performed. We evaluated the following factors related to phase I study designs 
for NP and SM: 1) ratio of MTD to starting dose; 2)  the number of dose escalations; 3) the 
number of patients enrolled; 4) time required to complete the study; and 4) total estimated 
cost of the study. 
Data Collection. Using databases such as PubMed, Medline, and ASCO Proceedings, 
searches for peer reviewed phase I studies of NP and SM were conducted using the search 
terms: MTD, preclinical, phase I, pharmacokinetics, and toxicity. Data was collected for 9 
NPs and matching SM anticancer agents. The NPs were Abraxane (albumin bound 
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paclitaxel), NKTR-102 (PEGylated irinotecan), liposomal vincristine, OSI-211 (liposomal 
lurotecan), liposomal vinorelbine, NK-105 (PEGylated paclitaxel), S-CKD602 (PEGylated 
liposomal CKD-602), IHL-305 (PEGylated liposomal irinotecan), MBP-426 (PEGylated 
liposomal oxaliplatin) (18, 56, 82-88). The SM were paclitaxel, irinotecan, lurtotecan, 
vinorelbine, CKD-602, and oxaliplatin (89-92). The NP and SM preclinical toxicology data 
was collected when available to determine the animal model used in defining starting dose in 
phase I clinical trials.   
For preclinical studies, the MTD found in rats and dogs were recorded. For phase I 
studies in patients with advanced solid tumors, the starting dose, the number of dose 
escalations from starting dose to MTD, number of patients, and the ratio of MTD to starting 
dose were recorded for each NP and SM. The MTD reported in all studies was defined as 1 
dose below the dose associated with the DLT. The DLT was defined as a grade 4 
hematologic or grade 3/4 non-hematologic toxicity in all studies. The dose escalation strategy 
for all of the reviewed phase I studies were performed using the conventional 3+3 modified 
Fibonacci design (93). The methods used to determine the starting dose in the phase I study 
of the NP and SM were the same. As per standard methods, toxicology studies were 
performed in rats and dogs.  If rats were the most sensitive species the starting dose in the 
phase I study was equal to 1/10 of the dose that was severely toxic to 10% of the animals on 
a mg/m2 basis. If dogs were the most sensitive species, the starting dose in the phase I trial 
was equal to 1/6 of the highest non-toxic dose in the dog on a mg/m2 basis. 
Cost Estimation. A cost estimation analysis was conducted in order to appraise the 
costs associated with a NP compared with a SM phase I study. Cost estimates were obtained 
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from the literature and were based on the class (NP or SM) of agent, number of treatment 
levels, and patients (94).  
Statistics. The null hypothesis was that there was no difference in the ratio of MTD 
to starting dose, dose escalations, and patients enrolled in a phase I clinical study between NP 
and SM. This was tested using a student’s t-test with alpha set at 0.05.  
 
 
Results 
 
          Ratio of MTD to Starting Dose. The starting doses, MTD, and ratios of MTD to 
starting dose for each SM are shown in Table 7. For SM, the mean ± SD (range) of the ratio 
of MTD to starting dose was 2.1 ± 1.1 (1.3 to 4.0). The starting doses, MTD, and ratios of 
MTD to starting dose for each NP are shown in Table 8. For NP, the mean ± SD (range) of 
the ratio of MTD to starting dose was 13.9 ± 10.8 (2.2 to 37.7). The ratio of MTD to starting 
dose of NP was approximately 7-fold higher than SM (P= 0.005). For the NP, including 
liposomal vinorelbine, NK-105 (PEGylated paclitaxel), S-CKD602 (liposomal CKD-602), 
and IHL-305 (PEGylated liposomal irinotecan), it was confirmed that the starting doses in 
clinical phase I studies were based on toxicology studies in dog (18, 84, 87, 88).  
Dose Escalations and Number of Patients.  The dose escalation strategy for all of 
the reviewed phase I studies were performed using the conventional 3+3 modified Fibonacci 
design (93). There was an increase in the number of dose escalations and patients enrolled on 
phase I studies of NP compared with SM. The total number of dose escalations and patients 
enrolled in a clinical phase I study for SM and NP are listed in Tables 7 and 8, respectively. 
The mean + SD (range) number of dose levels in a phase I clinical study for NP and SM were 
7.8 + 2.9 (4-13) and 4.1 + 1.5 (3-7), respectively (P = 0.008). A summary of mean + SD 
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(range) of MTD to starting dose, number of dose levels, and number of patients enrolled is 
provided in Table 9. There was a higher but not statistically different number of patients 
enrolled in a clinical phase I study of NP and SM (31.0 ± 9.3 and 25.1 ± 11.2, respectively), 
(P= 0.16.) 
Cost Estimation. The average cost per patient to complete a phase I clinical trial is 
approximately $35,000 (94). Assuming 3 patients per dose level based on the conventional 
3+3 modified Fibonacci design, the cost of a SM or NP phase I clinical study would be 
$430,500 and $819,000, respectively. Excluding the NP agents that did not require an 
increased number of dose levels compared to their SM counterpart brings the cost of a 
clinical phase I study of a NP to approximately $966,000. The rationale and justification of 
the removal is detailed within the Discussion section. Thus, a phase I clinical study of two 
identical chemical entities administered as a standard SM or within a NP formulation results 
in an approximately two-fold difference in the overall costs.   
 
Discussion 
This is the first study or review highlighting major differences between NP and SM 
phase I clinical study design and outcomes. There was a significantly greater number of dose 
levels, time required to complete phase I studies, patient related resources and costs to 
conduct phase I studies of NP compared with SM. These results indicate the inefficiency in 
which phase I studies of NP are designed and/or carried out relative to SM.  The cause of 
observed differences in clinical phase I studies may be due to differences in the PK and PD 
of NPs, preclinical animal models used for toxicities of NP, or study design issues of NP 
compared to SM. 
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The PK of NP is more variable than SM. A meta-analysis compared differences in 
AUC CV% as a measure of variability between liposomal and non-liposomal anticancer 
agents (95). For liposomal agents, the mean ± SD of CV% of AUC was 65.6 ± 18.6.  For 
non-liposomal agents, the mean ± SD of CV% of AUC was 30.7 ± 16.0.  The ratio of 
liposomal to non-liposomal CV% of AUC for each pair was 2.7 (P<0.001) (Eq 1).  Similarly, 
the mean ± SD ratio of AUCmax to AUCmin at the MTD was 34.1 ± 41.9 for liposomes and 
3.6 ± 1.8 for non-liposomal drugs.  The ratio of liposomal to non-liposomal ratio of AUCmax 
to AUCmin for each pair was 16.7 (P<0.13).  The significantly higher and clinically relevant 
PK variability of NP compared to SM may be affecting the design and progression of phase I 
studies of NP agents.  Thus, studies need to be performed and methods developed to evaluate 
and predict the factors inducing the high PK and PD variability of NP (96-98, 98). 
A potential reason for the discrepancy between NP and SM in human phase I studies 
could be model selection in preclinical studies. When allometric scaling was used to compare 
the PK disposition of three different PEGylated liposomes (S-CKD602, Doxil, SPI-077) 
across species (mice, rats, dogs, and humans) at the MTD, the PK disposition in dogs was a 
consistent outlier from other animal models (81). Additionally, when a Dedrick Time 
Equivalent model was used, dogs had the highest CL and thus the lowest exposure of all 
three liposomal agents at the MTD (81). This suggests that dogs clear PEGylated liposomes 
faster than other species which results in a lower plasma exposure but are the more sensitive 
to NP toxicity at this lower exposure. Thus, using dogs to determine starting dose in man 
results in a dose that is lower than needed and consequently creates exposures that have a low 
probability of achieving response and/or inducing toxicity. This results in an increase in the 
number of dose levels, number of patients, and ratio of MTD to starting dose for NP 
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compared with SM. Physiologically-based pharmacokinetic modeling and allometric scaling 
have been previously used for many small molecule agents to predict human PK from animal 
data. Mahmood reported on the MTD of 25 small molecule anticancer drugs that could be 
used to predict the proper starting dose in humans (99). He concluded that the approach saves 
time and avoids many unnecessary steps in attaining the MTD in humans. This information is 
in contrast to NPs, which are not extensively metabolized, have greater PK variability 
compared with SM and the PK in animal models is not directly extrapolated to humans. (81). 
Although animal models have successfully predicted SM PK in humans in prior studies, the 
ability to predict NP PK in humans based on results in animal models appears to be more 
problematic. The inability to extrapolate NP PK to patients from animal models is most 
likely due to differences in the MPS across species.  Thus, the standard models and methods 
used for SM cannot be used for NP. Future studies are needed to determine the most 
appropriate animal model and scaling methods for NP. 
Another potential reason for an increased number of dose levels could be that NP 
have a lower toxicity than SM and therefore the dose of NP can be escalated to higher levels 
than SM. In vitro and preclinical studies have demonstrated that toxicity of PEGylated 
liposomal agents and other non-targeted NP carriers is less than the comparative SM (100-
102). For example, the cytotoxicity of mitomycin C was drastically reduced when prepared in 
PEGylated liposomes (103). It also has been clinically noted that the biodistribution pattern of 
liposomes can lead to a relative reduction of drug concentrations in tissues that are known to 
be sensitive to the drug (104). The biodistribution pattern is due to the unique PK profile that 
is obtained after administration of NP, such as increased plasma exposure (AUC) and 
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reduced CL of the inactive-encapsulated drug (18, 100). Generally, stable NP carriers have 
minimal drug release in the circulation which reduces toxicities in normal organs (18, 100).  
Of the NP 9 agents reviewed 4 studies stated that the starting dose was based on dogs 
within the clinical phase I study. One study (Abraxane) stated that dogs had a 
hypersensitivity reaction to the NP and the in the remaining 4 studies, no information was 
provided on the starting dose. There were three NPs that did not follow the trend of greater 
resources and time to complete the phase I study (e.g. greater ratio of MTD to starting dose) 
compared with SM.  Those were NP were liposomal vincristine, albumin bound paclitaxel 
(Abraxane), and liposomal irinotecan. These agents all exhibit “non-classical” NP properties 
and interesting aspects of their preclinical and clinical results provide rationale for why they 
can be removed from the analysis. 
A study conducted by Zhigaltsev, et al., compared drug loading and retention among 
liposome-encapsulated vinca alkaloids: vincristine, vinblastine, and vinorelbine (105). While 
vincristine had the greatest % drug retention after a single dose of the three tested vinca 
alkaloids, it had only approximately 56% or 78% drug retention after 24 hours for the 0.1 
w/wt and 0.3 wt/wt drug-to-lipid ratio formulations, respectively. This finding is in contrast 
to preclinical and clinical in vivo data of other liposomal anticancer agents which have a 
much greater % (i.e. 90-95%) drug retention during the first 24 hours and beyond (18, 29). 
One of the most compelling examples of low vincristine retention in liposomes comes from a 
study conducted by Sapra, et al., whose objective was to find an effective strategy for treating 
B-cell malignancies in a murine model of human B-cell lymphoma (106). Long-circulating 
sterically stabilized immunoliposome formulations of vincristine and doxorubicin were given 
to these mice. The liposomal vincristine formulation had a much faster drug release rate from 
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the liposomes than liposomal doxorubicin. Additionally, after normalization of drug load to 
lipid amount, the drug to lipid ratio was several fold higher for liposomal doxorubicin than 
for liposomal vincristine over a 48-hour period (106). Thus, the liposomal vincristine 
included in this review appears to have rapid CL and release of drug from the carrier and thus 
does not exhibit classic NP properties of prolonged circulation of encapsulated drug that is 
cleared by the MPS. Instead, the vincristine is rapidly released from the liposome and cleared 
via hepatic metabolism and thus acts more like a SM agent than the other NP included in this 
review. 
The PK and PD of IHL-305 were also different than other NPs. IHL-305 is a 
PEGylated liposome formulation of CPT-11. CPT-11 is a prodrug that must be converted to 
the active moiety SN-38 by carboxylesterase enzymes in vivo (107). The complexity of CPT-
11 metabolism goes further, to include active lactone and inactive carboxylate forms of both 
the CPT-11 and SN-38, which exist at an equilibrium dependent upon pH and binding 
proteins (108). The complexity of metabolism increases with the involvement of genetic 
polymorphisms in uridine diphosphate glucuronosyltransferases (UGT) isoform 1A1, 
(UGT1A1), which is responsible for glucuronidation of SN-38 (109). Therefore, it is unclear 
whether differences in phase I outcomes are observed due to IHL-305 formulation, or due to 
the dosing of a pro-drug that is dependent upon many factors for metabolism.  
The phase I starting dose of albumin bound paclitaxel was not based on the dog 
toxicology studies because dogs had a hypersensitivity reaction to human albumin which lead 
to an early termination of toxicologic studies in dogs (110). Therefore, the starting dose of 
albumin bound paclitaxel was based on toxicology studies in non-human primates. Dogs 
appear to be inherently sensitive to the toxicologic effects of NPs, as evidenced through 
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toxicology studies as well as allometric scaling (81). The starting dose of albumin bound 
paclitaxel based on toxicity studies in non-human primates was most likely higher than 
would have been determined based on toxicology studies in dogs.  Thus, the number of dose 
levels from the higher starting dose to the MTD of albumin bound paclitaxel was less than 
other NP in the review. This highlights the potential benefits of performing toxicologic and 
pharmacologic studies of NP in non-human primates instead of dogs as the non-rodent 
species of choice. 
There are major differences between the design and performance of phase I studies of 
NP compared with SM. There is a significant difference in the number of dose levels and 
ratio of MTD to starting dose as well as increased number of patients enrolled and overall 
costs associated with studies of NP versus SM. These findings indicate that patients are being 
treated at doses that are very low and unlikely to produce toxicity and/or response. This 
undoubtedly leads to an inefficient use of patient resources, time, and funding. The potential 
primary cause of these issues in phase I studies of NP is that the low starting dose results 
from the use of an inappropriate toxicology model, which appears to be dogs or the ability to 
escalate the dose of NP higher. An alternative non-rodent model such as non-human primates 
may be more suitable.  
 There is preliminary evidence that suggests that factors associated with the MPS may 
contribute to NP PK and PD variability. Thus, there is a compelling need to identify the 
factors associated with MPS function in order to improve the preclinical and clinical studies 
of NP. It will be essential to further test whether the PK of NP can be scaled across species 
using various measurements and surrogates of the MPS, such as monocyte and macrophage 
activity or function, genetics, complement, or cytokines. In addition, the most appropriate 
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animal models for GLP toxicology studies must be identified. Identification of the correct 
animal model may drastically decrease the number of dose levels, patients, and costs 
associated with phase I clinical studies. Additionally, there must be exploration into new 
study designs for phase I studies of NP, as the unique pharmacology of NP agents may not be 
amenable to trial designs established for SM.   
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Table 7. Summary of Starting Dose, MTD, and Ratio of MTD to Starting Dose in 
Patients with Refractory Solid Tumors in Phase I Clinical Trials of Small Molecule 
Anticancer Agents. 
 
Small 
Molecule 
(SM) 
Starting 
dose 
(mg/m2) 
MTD 
(mg/m2) 
Ratio of MTD 
to starting 
dose 
Total 
number of 
dose levels 
Total 
number of 
patients 
vincristine 0.5 0.75 1.5 3 30 
irinotecan 240 320 1.3 4 34 
CKD-602 0.5 0.7 1.4 3 16 
paclitaxel 70 100 1.4 4 20 
vinorelbine 35 40 1.1 3 13 
oxaliplatin 45 135 3.0 7 44 
lurtotecan 0.3 1.2 4.0 5 19 
Mean ± SD 
(range) 
  2.0 ± 1.1 
(1.1-4) 
4.1 ± 1.5  
(3-7) 
25.1 ± 11.2 
(13-44)  
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Table 8. Summary of Starting Dose, MTD, and Ratio of MTD to Starting Dose in 
Patients with Refractory Solid Tumors in Phase I Clinical Trials of Nanoparticle 
Anticancer Agents. 
 
Carrier Mediated 
Agent (NP) 
Starting 
dose 
(mg/m2) 
MTD 
(mg/m2) 
Ratio of 
MTD to 
starting dose 
Total number 
of dose levels 
Total 
number of 
patients 
albumin bound 
paclitaxel 
135 300 2.2 4 19 
*NKTR-102 
(PEGylated 
irinotecan) 
58 144 2.5 5 27 
*liposomal vincristine 0.5 2.4 4.8 6 28 
OSI-211 (liposomal 
lurtotecan) 
0.15 1.8 12.0 7 37 
*liposomal 
vinorelbine 
2 28 14.0 7 30 
*NK-105 (PEGylated 
paclitaxel) 
10 180 18.0 7 19 
*S-CKD602 
(PEGylated liposomal 
CKD-602) 
0.1 2.1 21.0 13 45 
*IHL-305 (PEGylated 
liposomal irinotecan) 
7 160 22.9 10 42 
MBP-426 (PEGylated 
liposomal oxaliplatin) 
6 226 37.7 11 39 
Mean + SD (range)   13.9 ± 10.8 
(2.2-37.7) 
7.8 ± 2.9  
(4-13) 
31.8 ± 9.5 
(19-45)  
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Table 9. Comparison of Ratio of MTD to Starting Dose, Number of Dose Levels, and 
Number of Patients Enrolled on Study for Clinical Phase I Studies of Nanoparticle and 
Small Molecule Anticancer Agents. 
 
 
 Ratio of MTD to 
starting dose 
Number of dose 
levels 
Total number of 
patients 
NP Mean ± SD 
(range) 
13.9 ± 10.8 7.3 ± 2.9 31.0 ± 9.3 
SM Mean ± SD 
(range) 
2.0 ± 1.1 4.1 ± 1.5 25.1 ± 11.2 
Comparison of NP vs. 
SM; two sample t-test 
P= 0.005 P= 0.008 P= 0.16 
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CHAPTER IV 
 
A PILOT STUDY TO EVALUATE CELLULAR FUNCTION ASSAYS AS 
PHENOTYPIC PROBES OF THE MONONUCLEAR PHAGOCYTE SYSTEM IN 
PATIENTS WITH RECURRENT EPITHELIAL OVARIAN CANCER4 
 
Introduction 
 Nanoparticles (NPs), which include PEGylated liposomes, are novel drug delivery 
platforms that have the potential to improve tumor drug exposure and reduce accumulation in 
normal tissues more so than their small molecule counterparts (8, 12, 111). The 
pharmacokinetics (PK) of NPs is dependent upon the carrier and not the drug encapsulated 
within the carrier until the drug gets released from the carrier (3, 8, 12, 112). The drug that 
remains encapsulated within NPs, or linked to a conjugate or polymer is an inactive prodrug, 
and thus the drug must be released from the carrier in order to be active. After the drug is 
released from the carrier, the PK disposition of the drug will be the same as that following 
administration of the non-carrier form of the drug (8, 12, 111).  
 The PK disposition of PEGylated liposomal formulations of CKD602 (S-CKD602), 
doxorubicin (Doxil®), and cisplatin (SPI-077), have been evaluated in preclinical models and 
patients (29, 54, 113). The ability to extrapolate animal data to predict PK parameters in 
humans is an essential step in drug development (60). We have previously explored the use of 
allometric scaling to predict the PK of PEGylated liposomal agents across species (81). Our 
study indicated that while a relationship exists between species body weight and clearance 
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  Caron WP, Lay JC, Fong AM, La-Beck NM, Kumar P, Newman SE, Zamboni BA, Crona DJ, Monaco J, 
Zhou H, Clarke-Pearson DL, Brewster WR, Van Le V, Bae-Jump VL, Gehrig PA, Zamboni WC. Cellular 
function of the mononuclear phagocyte system as a phenotypic probe for PEGylated liposomal doxorubicin 
pharmacokinetics and pharmacodynamics in patients with recurrent ovarian cancer. Journal of 
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(CL), there is considerable variability in PK among species, particularly when scaled by 
conventional and non-conventional parameters. Thus, the development of new methods of 
scaling and/or measures of NP interaction at the biological level are warranted to further 
explore the variability observed in NP PK.  
Studies suggest that the significantly high and clinically relevant interpatient 
variability in the PK and pharmacodynamic (PD) disposition of NP anticancer agents is 
related to the function of monocytes and dendritic cells (MO/DC) of the mononuclear 
phagocyte system (MPS) (114, 115). The MPS is defined as a group of cells having the ability 
to ingest large numbers of particles (13). These cells, comprised of MO/DC circulating in the 
blood, fixed macrophages of various connective tissues, Kupffer cells in the liver, and 
macrophages in the lymph nodes, bone marrow, and spleen, serve as a potential CL pathway 
for NPs (13-15).  We have previously reported a significant relationship between the PK and 
PD of S-CKD602 and changes in circulating monocyte numbers and absolute neutrophil 
count (ANC) (115). The results of our previous study suggest that monocytes are more 
sensitive to toxic effects of S-CKD602 compared with neutrophils and that the increased 
sensitivity appears to be related to the liposomal formulation and not the small molecule 
drug, CKD-602, encapsulated inside the liposome. Thus, blood monocytes may play a key 
role or be a surrogate marker for NP CL in patients.   
Epithelial ovarian cancer (EOC) is a disease characterized by large numbers of 
peritoneal MO and macrophages, the primary cells of the MPS (116). As a result of high 
relapse rates several chemotherapeutic strategies have been developed for this patient 
population. PEGylated liposomal doxorubicin (PLD) is frequently used second- and third-
line for the treatment of recurrent EOC and is one of the few FDA approved NPs currently 
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available (96). However, in the second-line treatment of platinum refractory EOC, PLD 
achieves overall response rates of only 14-20% (116, 117). Moreover, there is significant 
variability in the PK and PD associated with PLD. Therefore, some patients are much more 
likely to receive a non-efficacious or toxic, particularly palmar-plantar erythrodysethesia 
(PPE), response (46). Thus, there is a compelling need to guide PLD dosing in order to 
improve the response rate and quality of life for women with EOC (60, 118-121).  
In general, one approach to improve the treatment of patients is to identify and 
employ a phenotypic probe to individualize therapy (122). A phenotypic probe is a test or 
agent than can be administered to a patient as an indicator of the PK and/or PD disposition of 
a drug, which can then be used to individualize therapy. Phenotypic probes measuring 
cellular function in blood could be used to evaluate the relationship between activity of the 
MPS and the effect on NP PK and PD in a relatively noninvasive fashion. The objective of 
this study was to evaluate phenotypic probes of MPS function in blood as predictors of PK 
and PD of PEGylated liposomal agents in animal models and patients. The function of 
MO/DC and polymorphonuclear leukocytes (PMNs) of the MPS in blood was evaluated 
using phagocytosis and reactive oxygen species (ROS) production.  
 
Materials and Methods 
 The preclinical studies were approved by the UNC Institutional Animal Care and Use 
Committee (IACUC). The clinical studies were approved by the Committee for the Rights of 
Human Subjects (Institutional Review Board) at the University of North Carolina at Chapel 
Hill.  All patients were advised of the purpose, procedures and associated risks and gave 
written informed consent. 
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Phenotypic and PK Studies in Preclinical Animal Models and Patients. 
Phenotypic studies of MPS function and PK of PEGylated liposomal agents were performed 
in mice, rats, dogs and patients with refractory solid tumors as part of clinical phase I studies 
(29, 53, 55, 57, 60). A blood sample was obtained using a sodium heparinized tube from each 
of the species in order to assess MO/DC phagocytosis and ROS production using FCM 
(methods are detailed in EOC clinical study).  Blood samples were obtained prior to 
administration of liposomal agents in triplicate in each species. 
  S-CKD602, PLD, and SPI-077 were administered to SCID mice, Sprague-Dawley 
rats, beagle dogs and as part of phase I clinical studies as described previously (29, 53-55, 57, 
60). Serial blood sampling times and analytical methods used to determine sum total 
nanoparticle concentrations are also provided in these previously published studies. The 
concentration versus time data was imported into Phoenix WinNonlin Version 6.1 (Pharsight 
Corp., Mountain View, CA) and a noncompartmental analysis was used to determine CL in 
each species. 
PLD PK and PD Studies in EOC 
Inclusion Criteria. Women receiving PLD as part of their standard of care treatment 
for recurrent EOC were eligible for enrollment in this study. Patients had to be > 18 years of 
age and have a documented hysterectomy or negative pregnancy test.    
Clinical Study Design. Baseline characteristics and treatment regimens of the 10 
women enrolled are listed in Table 11.  Patients were administered standard pre-medications 
including dexamethasone 10 mg, diphenhydramine 25 mg, famotidine 20 mg, and 
ondansetron 8 mg all IV x 1 30 minutes prior to PLD. Patients were administered PLD at 40 
mg/m2 alone or PLD at 30 mg/m2 IV x 1 over approximately 1 hour in combination with 
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carboplatin infused IV x 1 over 30 minutes at a dose to achieve AUC = 5 (Calvert equation).  
Serial blood PK samples were obtained at baseline prior to the administration of PLD or PLD 
with carboplatin, at the end of infusion (EOI), and 1, 3, 24, 48, 72, 96, 192, and 672 hours 
after the administration of PLD. Plasma was processed immediately and the encapsulated and 
released components of PLD were separated using solid phase separation methods as 
described previously (18, 29, 111). Noncompartmental analysis was performed using Phoenix 
WinNonlin Version 6.1 to calculate PK parameters (Table 12).  
 Blood (3 mL) was obtained at baseline, 48, 72, and 96 hours to test the function of 
MO/DC. At each visit, vital signs were obtained, physical examinations and blood work was 
performed at the discretion of the individual physician, and patients were asked about any 
adverse symptoms they experienced, including but not limited to nausea/vomiting, PPE, 
neuropathy, and stomatitis. Grade of toxicity was determined by the National Cancer 
Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE, version 4.03). 
Patients were followed until disease progression or toxicity necessitated discontinuation of 
PLD.  Progression free survival (PFS) was determined by RECIST criteria (version 1.1).   
Phenotypic Probes. Innate immune function (phagocytosis and ROS production) of 
peripheral blood monocytes and PMNs was assessed by flow cytometry. Initially data were 
used to determine whether there was a relationship between cellular function and PK among 
species. A single 5 mL blood sample was taken from each species (at n= 3) used in the PK 
studies to test cellular function. Data were then used to assess possible correlations between 
cellular function (phagocytosis and ROS production) and PK (CL of PLD) and PD (PFS and 
PPE) of PLD in women with recurrent EOC. Studies of MPS function prior to the 
administration of PLD in each patient were used to predict PLD PK and PD. Additionally, 
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the changes in cellular phagocytosis and ROS over time was assessed within and between all 
patients.  
 Flow cytometry was performed in the UNC Flow Cytometry Core Facility using a 
Dako Cyan flow cytometer and data were analyzed using FlowJo software v 7.6.5.  For both 
the phagocytosis and ROS assays, MO/DC and PMN populations were gated based on light 
scatter properties (FSC vs. SSC) and subsequently plotted for histogram analysis (Figure 9). 
The proportion of positive cells (i.e. cells which exhibit fluorescence) was determined as 
those events, which shifted to the right out of the “negative” region on the fluorescence 
intensity scale (FITC). Mean fluorescent intensity (MFI) of the positive cell population 
served as an index of phagocytic or ROS activity.   
Phagocytosis Assay. Twenty µL of FITC-labeled opsonized E. Coli bacteria bio-
particles (1 x 108 particles/mL) (Orpegen Pharma, San Diego, CA) were added to 100 µL of 
whole blood and incubated for 10 minutes at 37°C. Additional samples kept on ice (0°C) 
served as a negative control. After incubation, 100 µL of Trypan blue was added to quench 
extracellular fluorescence. Phagocytic activity (number of bacteria internalized per cell) was 
quantified as the MFI of the “positive” cells. 
ROS Production Assay. ROS was assessed in MO/DC in response to no stimuli and 
to a variety of stimulants, including opsonized non-fluorescent E. Coli as a phagocytic 
stimulus, N-formyl-methionine-leucine-phenylalanine (fMLP) as a physiologic peptide, 
phorbol myristate acetate (PMA) a synthetic ester, and PBS as a control (no stimulus; 
baseline measurement). Following a 10 minute exposure to the stimulus, non-fluorescent 
dihydrorhodamine (DHR) 123 (Orpegen Pharma, San Diego, CA) was added to the samples 
as a fluorogenic substrate, which, following intracellular oxidation was converted to 
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fluorescent rhodamine (R) 123. MFI of R 123 fluorescence served as a quantitative measure 
of intracellular oxidative activity.  
Statistics 
 All statistical analyses were performed using SAS v 9.2 (Cary, NC) software.  Simple 
linear regression was used to explore the linear relationship between two continuous 
variables, including the relationship between MO/DC or PMN cellular function and PK (CL) 
or PD (PPE grade and PFS) The coefficient of determination, R-squared (R2) was used to 
measure the linear association between PK/PD outcomes and cellular function. The 
relationship between CL and phagocytosis was evaluated using analysis of covariance 
(ANCOVA) including a term for treatment type (PLD vs. PLD + carboplatin). A Kruskal-
Wallis test was used to test for differences in median MFI between patients and within 
patients over the course of cycle 1. A Cox proportional hazards model, using progression-
free survival as the outcome variable and phagocytosis as a covariate, was used to estimate 
predicted progression-free survival at differing levels of phagocytosis. Alpha was set at 0.05 
for all statistical tests and all p-values are two-sided. 
 
Results 
Relationship Between Cellular Function and PEGylated Liposome PK in 
Preclinical Models and Patients with Refractory Solid Tumors. The relationship between 
phenotypic probes of MPS function and PK of PEGylated liposomal agents was evaluated in 
preclinical tumor models and in patients with refractory solid tumors as part of phase I 
studies. There was a direct linear relationship between MPS activity and the CL of 
PEGylated liposomes across mice, rats, dogs and humans. The average Mean Fluorescence 
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Intensity (MFI) in the MO/DC population following the phagocytosis assay in the 4 species 
evaluated was correlated with CL of PLD (R2= 0.92), S-CKD602 (R2= 0.92), and SPI-077 
(R2= 0.77) as shown in Figure 10A. There was a similar trend observed when comparing the 
production of ROS across species without any stimulus (baseline) with CL of PLD (R2= 
0.77), S-CKD602 (R2= 0.77), and SPI-077 (R2= 0.66) (Figure 10B). The relationship was 
also seen between production of ROS when stimulated with PMA and CL of PLD (R2= 
0.77), S-CKD602 (R2= 0.77), and SPI-077 (R2= 0.66). 
Phenotypic Probes Predict PLD PK in Patients with EOC. The relationship 
between phenotypic probes of MPS function and PLD PK was evaluated in patients with 
EOC.  On day 1 of the study, phagocytosis and ROS production were assessed in MO/DC 
prior to the start of the PLD infusion in patients with EOC (n=10).  A linear relationship (R2= 
0.43, P= 0.04) was found between MFI of the phagocytic cells and PLD CL for all patients, 
shown in Figure 11A. A relationship between MFI of ROS production without stimulus at 
baseline and PLD CL for all patients was also observed as shown in Figure 11B (R2= 0.61, 
P= 0.008).  
There was also a relationship between the ROS probe with the addition of a stimulant, 
and PLD CL in all patients at baseline (Table 10). The only stimulant that did not show a 
strong relationship in all patients was PMA, (R2= 0.23). PMA was also the only probe that 
had lower association in the PLD alone versus PLD + carboplatin group. However, the other 
oxidative burst stimulants performed similarly to the phagocytosis probe and also 
demonstrated stronger relationships in the cohort of patients which received PLD alone vs. 
PLD + carboplatin. 
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 A multiple linear regression model was also used to examine the relationship between 
phagocytosis and doxorubicin clearance adjusting for treatment.  The model had doxorubicin 
CL as the dependent variable and phagocytosis and treatment (an indicator variable for PLD 
or PLD + carboplatin) as the independent variables.  This model, which results in two 
intercepts (intercept for PLD alone = β0 and intercept for PLD plus carboplatin = β0 + 
βtreatment) and a common slope (βphagocytosis), suggests a positive linear association between 
phagocytosis and CL of PLD (βphagocytosis=0.04, p=0.07) where patients with higher MPS 
function have a higher CL of PLD (Figure 12).  Patients on PLD plus carboplatin (dotted 
regression line) had somewhat lower doxorubicin clearance compared to patients on PLD 
only (solid regression line), however the treatment effect was not significant (βtreatment=6.06, 
p=0.38).  
The correlation between either phagocytosis or ROS production in PMNs and PLD 
CL failed to reach statistical significance in either the total patient population or 
subpopulations. In the study 87.4% ± 10.9% of gated MO/DC in patients tested positive to 
the phagocytosis or ROS probe. Therefore, differences in MFI between patients were due to 
cellular function variability and not the ability of the assay to detect positive events.  
Cellular Function Over Time in Patients with EOC. The cellular function of 
MO/DC and PMNs was also assessed over time in the first cycle of PLD with or without 
carboplatin. Phagocytosis measured in both MO/DC (P= 0.85) and PMNs (P= 0.66) were not 
significantly different in patients over the course of measurement (days 1, 3, 5, 28).  The 
same held for ROS (no stimulus) in both MO/DC (P= 0.37) and PMNs (P= 0.25) over cycle 
1. On day 1, just prior to PLD administration, the MFI of ROS (no stimulus) in all patients 
ranged from 7.4 to 117.05. The mean ± SD MFI of ROS was 39.1 ± 36.4 on day 1. The MFI 
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for ROS in patient 3 was 117.05. Without patient 3, the mean ± SD MFI for ROS of the other 
9 patients was 30.5 ± 25.5.   
PLD PK Predicts PD in Patients with EOC. The relationship between PLD PK and 
PD [Progression Free Survival (PFS) and PPE) was evaluated. There was a significant 
association observed between encapsulated PLD exposure (AUC) and PFS (days) in the four 
patients receiving PLD alone who progressed while on PLD treatment (R2= 0.88, P< 0.0001) 
(data not shown). For the 5 patients who experienced PPE during the course of the study, 
there was a non-statistically significant relationship between their exposure to PLD and the 
highest grade of PPE reported, (R2= 0.08, P= 0.6) (data not shown). 
Phenotypic Probes Predict PLD PD in Patients with EOC. All patients enrolled in 
the study were followed until disease progression and/or PLD related adverse events required 
discontinuation of PLD treatment. PLD could be stopped for grade 3/4 myelosuppression, 
stomatitis, PPE, or treating physician discretion. Patient 3 had rapidly progressive disease 
and died prior to the start of cycle 2 of PLD. Three additional patients (1, 8, and 10) had 
progressive disease while on PLD. For these four patients, the phenotypic probes of 
phagocytosis (R2= 0.77, P= 0.02) and ROS (R2= 0.67, P< 0.0001) prior to PLD 
administration were predictive of PFS in days (data not shown). A cox proportional hazard 
model with phagocytosis as the independent variable was fit and we determined the predicted 
probability of progression-free survival based on the level of MO/DC phagocytosis (Figure 
13) using the three quartiles of blood phagocytosis, (Q1=345 (MFI) med=486 (MFI), and 
Q3= 621 (MFI).   
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Discussion 
We have previously reported a relationship between physiologic parameters such as 
body weight, organ blood flow, and monocyte count and the PK of PEGylated liposomes in 
animal models and in patients with refractory solid tumors (81). In this prior study, variability 
in the PK, particularly CL and exposure as measured by area under the concentration versus 
time profile (AUC) was noted across species. However, this current study is the first study to 
look at a plausible biological explanation for the variability in PK of NP across species and in 
a clinically relevant patient population. We found that the phagocytic capacity and level of 
ROS production in MO/DC in blood of mice, rats, dogs, and humans is correlated with the 
CL of PEGylated liposomal agents across all species. This finding, in addition to our prior 
clinical studies of PEGylated liposomal CKD-602 (S-CKD602) prompted the development of 
a second clinical study that used the same phenotypic probes of MPS function to predict PLD 
PK and PD in patients with recurrent EOC (18). For the first time, we have demonstrated that 
a fast and inexpensive blood test of MPS function obtained prior to the administration of 
PLD can be used to predict PK, efficacy and toxicity and can be used to individualize 
therapy. These probes may also predict PK and PD of other NP, conjugates, monoclonal 
antibodies and antibody drug conjugates (ADC) in animal models and in patients. 
We observed a linear relationship between MPS activity and the CL of PEGylated 
liposomes across species. The phagocytic capacity and production of ROS of MO/DC was 
correlated with CL of the PEGylated liposomes PLD, S-CKD602, and SPI-077. The 
relationship was particularly noteworthy in MO/DC phagocytosis with the CL of PLD (R2= 
0.92), S-CKD602 (R2= 0.92), and SPI-077 (R2= 0.77). This was the first study reporting a 
relationship between MPS function in blood and CL of a NP across species, including 
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patients with cancer.  The phenotypic probes developed in this study can be used to profile 
various types of NP agents in preclinical models and patients.  In addition, the probes of MPS 
function can be used to determine which animal model(s) predict MPS function and PK and 
PD of NP in patients. 
 In order to evaluate the interaction of NPs with the MPS in a clinically relevant 
patient population and building upon our previous findings, we performed the first clinical 
study using circulating MO/DC in blood as a surrogate measure of the MPS function to 
predict PLD PK and PD (PFS and PPE toxicity).  Results of the study reported here 
demonstrate that probes of MPS function predict PLD PK and PD. There was a linear 
relationship between encapsulated doxorubicin CL and both phagocytosis (R2 = 0.43, P= 
0.04) and ROS activity (R2 = 0.61, P= 0.008) in blood MO/DC.   
 Consistent with the association between MPS probes and PLD PK, there was an 
association between phagocytosis (R2 = 0.77, P= 0.02) and ROS (R2 = 0.67, P= 0.06) probes 
with PFS in the 4 patients who progressed while on PLD alone at the time of manuscript 
preparation. These results suggest that patients with higher MPS activity have a faster CL of 
PLD and a lower plasma exposure, which may be associated with less drug being available 
for delivery to the tumor and lower response. This relationship is further demonstrated by a 
Cox proportional hazard model that includes all 10 patients and assesses the relationship of 
the phagocytosis probe and its influence on the outcome of progression-free survival.  
 With these preliminary findings, we have observed that phenotypic probes may 
potentially provide valuable information toward dose individualization. Probes could be used 
to measure MPS function in each patient prior to administration of PLD and then the dose of 
PLD may be adjusted based on MPS function and target plasma exposure (AUC). This is a 
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similar process as that used to individualize carboplatin dose based on renal function and 
target plasma AUC (123, 124). One MPS probe also were predictive of PPE toxicity in 
patients, as the ROS production at baseline was correlated with PPE grade on a scale of 0-5 
(R2= 0.56), however this will need to be validated in a larger cohort of patients. If probes 
may be used to determine efficacy such as PFS, they could also indicate early in the 
treatment plan whether PLD is a worthwhile option for the particular patient.  
When comparing the association between phagocytosis or ROS phenotypic probes 
and encapsulated doxorubicin CL, patient 3 consistently had the highest value in both 
measures. All data points were included in this study of 10 patients; however, patient 3 
noticeably improves the relationship using simple linear regression. Interestingly, patient 3 
had the most extensive disease burden of all patients enrolled. An MRI taken just prior to her 
start on the study indicated moderate volume ascites and multiple tumor masses abutting the 
liver, the largest measuring 5.2 x 3.7 cm. Thus, the higher MPS activity and CL of PLD in 
this patient may be explained in part by the reported relationship between tumor metastases 
in liver and the CL of NP (50)(50).  Our group has previously reported that patients with 
primary or metastatic tumors in their liver (n= 21) had a significantly (P = 0.02) higher CL of 
the NP S-CKD602 compared with individuals without tumors in their liver (n= 8) (120). This 
suggests that patients with tumors in their liver may require a higher dose of NP compared 
with patients without tumors in their liver. This is a paradigm shift from what is normally 
seen with small molecule agents where patients with tumors in their livers have a reduced CL 
of drugs that are metabolized by phase I and II enzymes (125)(125). 
 One potential reason for the difference in the relationship between encapsulated 
doxorubicin CL and cellular functional assays between the PLD only and PLD in 
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combination with carboplatin could be secondary to platinum effects on the cellular function 
of the MPS cells. The effect of platinum agents on monocytes has been explored in vitro by 
Nielsen, et al (126). In this study, a 1 µM exposure of cisplatin for 60 minutes was shown to 
selectively inhibit chemotaxis, which can then also inhibit phagocytosis, in monocytes 
isolated from venous blood of healthy volunteers (126). Fumarulo, et al., also reported an in 
vitro chemotaxis inhibition by cisplatin using peritoneal macrophages of the rat (127). In 
addition, an in vivo study has reported impaired blood monocyte chemotaxis in cancer 
patients ≥ 20 hours after receiving cisplatin at 20 mg/m2 IV x 1(128). Based on these studies 
and our results, the quick onset of chemotaxis and phagocytosis inhibition by cisplatin could 
explain a lack of functioning monocytes in the area of drug uptake and subsequently a lower 
NP CL.     
 We are aware that, due to the relatively small number of subjects in this pilot study of 
PLD in patients with EOC, some of our statistical comparisons are likely underpowered, 
which may have affected our ability to detect significant relationships. Nevertheless, we were 
able to observe suggestive associations between monocyte function and PLD CL, PFS and 
PPE toxicity in these exploratory, rather than confirmatory analyses. Moreover, the data 
show that the patient with the highest probe activity had a different pathophysiology than the 
other 9 patients enrolled. Not only did this patient have the most extensive disease burden, 
but the highest ROS measurement. These results may indicate an environment of oxidative 
stress and imbalanced redox systems (129).   
 This study shows that the CL of PEGylated liposomes across 4 different species is 
related to the cellular function of MO/DC. MPS function can be easily measured using flow 
cytometry (FCM) and serve as a phenotypic probe to relatively non-invasively predict the PK 
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and PD for PLD in women with recurrent EOC. Phenotypic probes are reproducible, highly 
translatable, and readily transferable to clinical practice as both the cell based assays and 
flow cytometry analysis are available in hospitals and are straightforward to perform. We 
demonstrated that phenotypic probes can predict PLD PK, the PLD PK predicts PD and 
ultimately that the phenotypic probes can predict PLD PD. The ability to employ a clinical 
test that is fast, inexpensive and can be used to individualize PLD therapy and potentially 
treatment with other NP agents in patients is of great potential value. A randomized clinical 
trial comparing response and toxicity of PLD in patients with EOC treated with standard 
PLD based on body surface area (BSA) compared with the dose of PLD individualized based 
on our MPS probes is planned.   
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
 81 
Table 10.  Coefficients of Determination (R2) Between the Oxidative Burst Probes and 
PLD CL in the 10 Patients Enrolled in the Study. Values are Reported for Patients who 
Received PLD (Only) or PLD + Carboplatin as Their Standard Therapy for Recurrent 
EOC. 
 
 
 
 
 
‡P < 0.001 
*P < 0.05 
 
 
 
 
 
 
 
 
 
 
Stimulant All Patients 
(R2) 
PLD Only 
(R2) 
PLD + carboplatin 
(R2) 
No stimulant 
(baseline cell ROS 
production) 
0.61‡ 0.61* 0.0005 
E. Coli (particulate) 0.46* 0.44 0.26 
fMLP (physiologic) 0.54* 0.48 0.14 
PMA (synthetic) 0.23 0.21 0.59 
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Table 11. A Summary of the Baseline Characteristics of the Patients Enrolled. 
 
 Age (years) Race Weight (kg) BSA Chemotherapy 
1 63 C 54 1.63 PLD  
2 51 C 73 1.9 PLD 
3 57 C 71 1.78 PLD 
4 67 C 89 1.96 PLD + 
carboplatin 
5 76 C 91 1.91 PLD 
6 51 C 72 1.84 PLD + 
carboplatin 
7 53 C 94 1.94 PLD + 
carboplatin 
8 75 C 48 1.46 PLD 
9 44 C 77 1.91 PLD + 
carboplatin 
10 52 AA 116 2 PLD 
Mean ± SD 
Or Total 
59 ± 10.9 9 CC         
1AA 
78 ± 20 1.8 ± 0.2 6 PLD alone 
4 PLD + 
carboplatin 
 
 
 
 
 
C = Caucasian, AA = African American 
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Table 12. PEGylated Liposomal Doxorubicin Plasma PK Parameters in Patients with 
Recurrent EOC. 
  Doxorubicin Plasma PK Parameters 
  Encapsulated Released Ratio of 
AUCreleased 
to 
AUCencapsulated 
Parameter 
CL AUC t½ Vd CL AUC t1/2 Vd 
Units (mL/h) (ng/mL*h) (h) (mL) (mL/h) (ng/mL*h) (h) (mL) (ng/mL*h) 
Mean ± 
SD 25.7 ± 12.1 
2,898,782 
± 974,518 
79.6 
± 
25.3 
2,569 
± 
502 
253.0 
± 
175.8 
243,541 ± 
171,578 
189.7 
± 
252.6 
40,166 
± 
34,838 
0.10 ±  
0.05 
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Figure Legends 
 
1.     Figure 9.  Representative result of the phagocytosis phenotypic probe in a patient whole 
blood sample. (A) A patient whole blood sample separated by forward scatter (FSC) and side 
scatter (SSC), which differentiates blood cells based on their size and granularity, 
respectively. This separation indicates three distinct cell populations, lymphocytes, MO/DCs 
(gated together) and PMNs or polymorphonuclear leukocytes (PMNs). (B) A sample that has 
been incubated for 10 minutes with FITC-labeled E. Coli and kept on ice. Phagocytosis was 
negative in all three cell populations. (C) A sample that has been incubated for 10 minutes 
with FITC-labeled E. Coli and placed in a 37°C water bath. MO/DC and PMNs have shifted 
in the FITC channel, indicating particle uptake. (D)  Histogram overlay of events in the 
MO/DC gate in panel A from a control (Black) and test sample (Blue). Events located within 
the “positive” region represent cells, which engulfed FITC-labeled E. Coli. The proportion 
and MFI of positive events serve as indices of phagocytic activity.  
2.     Figure 10. (A) Measuring phagocytosis and (B) production of ROS in MO/DC from blood 
samples of mice, rats, dogs, and patients can be predictive of PEGylated liposome CL. The 
ability to translate results of NP preclinical data to human patients may require measuring 
cellular function of the cells responsible for NP uptake and CL. The ability to predict PK of a 
NP prior to administration is of great potential clinical value and data suggests that certain 
phenotypic probes may accomplish this goal.  
3.   Figure 11. Measuring phagocytosis and production of ROS of MO/DC from patient blood 
samples at baseline (prior to the start of chemotherapy) might be predictive of encapsulated 
doxorubicin CL (A) Phagocytic activity (MFI) is significantly correlated with CL of 
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encapsulated doxorubicin in 10 patients (R2= 0.43, P= 0.04). (B) Production of reactive 
oxygen species (ROS) (MFI) is significantly correlated with CL of encapsulated doxorubicin 
in 10 patients (R2= 0.61, P= 0.008). 
4.     Figure 12. The multiple linear regression model with doxorubicin clearance as the dependent 
variable and phagocytosis and treatment (an indicator variable for PLD or PLD plus 
carboplatin) as independent variables.  Individual data points are represented as the symbols. 
The results suggest a positive linear association between phagocytosis and CL of PLD 
(β phagocytosis =0.04, p=0.07).  The observations for the two treatment types are denoted by 
x=PLD + carboplatin and open circle = PLD only.  The regression lines are displayed for the 
two treatment types (dotted line = PLD + Carboplatin and solid line = PLD only).  This 
model, which results in two intercepts (intercept for PLD alone = β0 and intercept for PLD 
plus carboplatin = β0 + βtreatment ) and a common slope (βphagocytosis), suggests that 
patients with higher MPS function have a higher CL of PLD.  Patients on PLD + carboplatin 
(dotted regression line) had somewhat lower doxorubicin clearance compared to patients on 
PLD only (solid regression line), however the treatment effect was not significant 
(βtreatment=6.06, p=0.38). 
5.     Figure 13. Progression free survival probability over time in days for 10 patients with 
recurrent EOC receiving PLD. Using the three quartiles of blood phagocytosis, (Q1=345 
(MFI) med=486 (MFI), and Q3= 621 (MFI), a cox proportional hazard model with 
phagocytosis as the independent variable can be fit to the data. The model suggests lower 
progression-free survival probabilities for higher levels of phagocytosis in MO/DC in blood. 
 
	  
	  
 86 
Figure 9. Representative Result of the Phagocytosis Phenotypic Probe in a Patient 
Whole Blood Sample. 
 
 
 
 
 
 
 
A.       FSC vs. SSC B.      Control: 0°C 
C.      Test: 37°C D.   Control: 0°C Test: 37°C 
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Figure 10. The Relationship Between MO/DC Function and PEGylated Liposome CL 
Across Species. 
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Figure 11. The Relationship Between Phagocytosis and Production of ROS of MO/DC 
from Patient Blood Samples at Baseline (Prior to the Start of Chemotherapy) and 
Encapsulated Doxorubicin CL 
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Figure 12. A Multiple Linear Regression Model Using Two Intercepts and a Common 
Slope Suggests a Positive Linear Association Between Phagocytosis and CL of PLD and 
a Difference Between Treatment Groups PLD and PLD + Carboplatin. 
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Figure 13. Predicted Probability of Progression-Free Survival as a Function of Blood 
Phagocytosis Separated by Quartiles. (Q1=345 (MFI) Med=486 (MFI), and Q3= 621 
(MFI). 
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CHAPTER V 
 
A COMPARISON OF THE CELLULAR FUNCTION OF CIRCULATING 
MONOCYTES/DENDRITIC CELLS AND TISSUE MACROPHAGES IN 
PRECLINICAL SPECIES 
 
 
 
As demonstrated in Chapter 2, PK parameters such as CL can be allometrically scaled 
across species for PEGylated liposomes (Figure 9). Additionally, in Chapter 3, we conclude 
that certain animals, particularly canines might not be appropriate models for basing first-in-
human NP doses from. In Chapter 4, we studied circulating MO/DC function in patients as a 
surrogate for the MPS. In this chapter, we explore how the function of blood cells from 
various preclinical species differs. Furthermore, we measure the function of resident tissue 
macrophages to determine the relative contribution of our surrogate to the overall system.  
In this study, we evaluated the MPS function in blood and tissues of mice, rats, dogs, 
and pigs. In mice, we evaluated MPS function in blood and spleen. In rats, we evaluated 
MPS function in blood, spleen, and liver. In dog, we evaluated MPS function in blood and in 
a liver section.  In pigs, we evaluate MPS function in whole blood. We also evaluated MPS 
function in mouse blood samples from regulated upon activation, normal T cells expressed 
and secreted (RANTES) and monocyte chemoattractant protein-1 (MCP-1) gene or receptor 
knockout SCID mice. RANTES and MCP-1 are also known by more current nomenclature as 
chemokine C-C motif ligands CCL5 and CCL2, respectively. 
Chemokines are small (8-10-kDa) inducible proteins or chemoattractant cytokines 
that have the ability to activate leukocytes and mediate inflammatory states (130). There are 
four different classes of chemokines, and it is the C-C or β-chemokines that exert their effect 
on monocytes, but not neutrophils (130). Chemokines do not only have an influence in 
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pathological states, but also play a role in the physiologic immune response, as evidenced by 
the activity of CCL2 and CCL5 (130, 131). CCL2 and its receptor CCR2 have been shown to 
be induced and involved in pathological states, but the migration of monocytes from the 
bloodstream across the vascular endothelium is required for routine immunological 
surveillance of tissues, and they could play a role here as well (130).  CCL5 is involved in the 
migration of many immune cells, including eosinophils, basophils, mast cells, monocytes, 
cytotoxic T lymphocytes, naïve CD4+ T cells, and memory T cells (131). CCL5 is believed to 
be intimately involved in the chemoattraction and activation of DCs (131).  
We hypothesized that tissue macrophages from liver and spleen would display a 
higher level of activity or greater MPS function than circulating MO/DC from whole blood. 
Additionally, we hypothesized that the function of circulating MO/DC from knockout mice 
would be lower than those in wild-type mice.  
 
Methods 
 
Animal Model Selection. Species of animals were selected based on standard animal 
models used for PK, efficacy and toxicity studies of nanoparticles, diversity and whether 
there was a matching PK data set for the model. For rats, dogs, and pigs, Sprague-Dawley, 
beagles, and pigs respectively, were selected. For mice, C57BL/6 mice were used as wild-
type and we also included CCL5 and CCL2 gene or receptor (CCR2) knockout mice. 
Splenic Macrophage Isolation. Spleens from 2 Sprague-Dawley rats and 2 of each 
SCID knockout mouse strain were harvested (performed by the UNC Animal Studies Core 
Facility). The macrophages collected from each tissue were pooled and then the functional 
assays were run in triplicate. The harvested spleen was placed in PBS and was transferred to 
a tissue culture dish with 5 mL RPMI containing complete growth medium (CGM) (PS, 
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NEAA, Glu, NaPyr, and FBS; with 0.05 mL β-ME per 50 mL media). The spleen was placed 
between 2 frosted glass slides using sterile forceps and physically homogenized. The cells 
from the homogenization process were added to the RPMI CGM in the petri dish, as well as 
tissue particulate that was not degraded. The suspension was transferred to a FACS BD 
Falcon tube and centrifuged at 400 x g for 5 minutes.  The media supernatant was removed 
and 1 mL of ACK lysing solution added. The tube was gently tapped to mix and the 
suspension was left to incubate for 10 minutes at room temperature in the dark. A 4 mL 
solution of the RPMI CGM was added to quench the reaction and then the cells were 
centrifuged at 400 x g for 5 minutes and the media supernatant removed. The cell pellet was 
then resuspended in 2 mL of RPMI and APC rat anti-mouse or mouse anti-rat CD11b 
antibody was added to the appropriate cell suspension. 
Kupffer Cell Isolation. For rat and dog liver, Kupffer cells were isolated per the 
methods previously published by Smedsrod and Pertoft in which a pure culture of Kupffer 
cells (KC), parenchymal cells (PC), and liver endothelial cells (LEC) can be simply and 
rapidly established (132). The KC collected from the rat livers were pooled and then the 
functional assays were run in triplicate. Single cell suspensions were first prepared from 
livers of rats (Sprague-Dawley) using perfusion with collagenase. The collagenase used was 
one that contained 440 units of collagenase activity and 45 units of unspecific proteolytic 
(“caseinase”) activity per milligram of protein. Previous studies have shown that this 
collagenase produced rapid and complete dispersion of the liver cells with high preservation 
of viability and endocytic capability.  
Liver perfusion. Rats were anesthetized with an intraperitoneal injection of ketamine 
(100 mg/kg) and xylazine (10 mg/kg). A two-step collagenase digestion method previously 
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described by LeCluyse et al. was followed (133). Briefly, the abdominal cavity was opened 
and loose sutures were placed around the inferior vena cava above the renal artery, as well as 
the portal vein. Following cannulation of the portal vein with an 18 gauge catheter, perfusion 
of the liver begun and the inferior vena cava was cut below the renal artery to relieve 
pressure. The liver was perfused at a flow rate of 20 mL/min with an EGTA-containing 
perfusion buffer. EGTA is present to chelate calcium (Ca2+) ions, leading to the disruption of 
cellular junctions. Two minutes after perfusion began, the thoracic cavity was opened, the 
heart cut and the suture around the inferior vena cava tightened in order to redirect the 
perfusion. After 10 min, the perfusion was switched to a collagenase (Type I; Worthington 
Biochemicals)-supplemented perfusion buffer (also containing Ca2+ for enzyme activity) and 
was continued until the liver appeared digested. The liver was removed from the carcass and 
placed in a petri dish containing culture medium. Forceps were used to disrupt the capsule 
and the liver was shaken gently to release cells into the medium. 
 After the perfusion was complete and only a white mesh of vessels remained, the cell 
suspension (referred to as the initial suspension) was filtered through nylon gauze with 50 
µm pores to remove the cellular aggregates and tissue debris.  The filter was rinsed with D-
PBS and then the initial suspension was centrifuged at 50 x g for 2 minutes at 4°C. The 
resulting pellet was PC-rich and the supernatant non-parenchymal cells (NPC) rich. Each 
component went through a subsequent sedimentation step with Percoll to further purify the 
three key cell groups: PC, KC, and LEC.  
 To purify cell subtypes, the NPC rich supernatant was adjusted to a total volume of 
40 mL with D-PBS and then divided into 4 10 mL fractions. Four 50 mL Falcon tubes were 
filled with a two-step Percoll gradient. The bottom (denser) layer consisted of 7.5 mL stock 
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isotonic Percoll (SIP) and 7.5 mL PBS yielding a density of 1.066 g/mL and an osmololaity 
of 310 mOsm. The overlaying top layer consisted of 5 mL SIP and 15 mL PBS, yielding a 
density of 1.037 g/mL and an osmolality of 300 mOsm. The 4 10 mL fractions of PC-rich 
supernatant were carefully layered on top of the Percoll gradients in the 4 Falcon tubes. The 
tubes were centrifuged at 800 x g for 15 minutes at 4°C. Upon centrifugation, cells 
distributed into 4 distinct zones. The upper zone or supernatant contained debris, damaged 
cells and a few viable NPC. The intermediate zone contained purified NPC, enriched in LEC, 
free of debris, erythrocytes and most PC. A second zone contained purified enriched in KC 
and the pellet consisted of PC, erythrocytes, and unidentified small white cells (presumably 
lymphocytes). The fraction containing KC (~ 15 mL) was pipeted from the suspension and 
diluted 1:1 with PBS. The fraction was then centrifuged at 800 x g for 10 minutes at 4°C. 
The cell pellet was resuspended in cell culture medium. This fraction has been identified as 
KC in the literature through a staining for peroxidase (134). The yield of KC from the rat and 
dog liver were approximately 2.4 x 106 cells/g of tissue. 
Blood Collection. Blood collection varied slightly for the animal species sampled. 
All blood samples acquired were put into a sodium heparinized tube. For mice and rat, the 
blood was taken via cardiac puncture where nearly the entire blood volume was collected.  
Phagocytosis Assay. Twenty µL of FITC-labeled opsonized E. Coli bacteria bio-
particles (1 x 108 particles/mL) (Orpegen Pharma, San Diego, CA) were added to 100 µL of 
whole blood or of tissue cells in suspension (isolation methods described above) and 
incubated for 10 minutes at 37°C. Additional samples kept on ice (0°C) served as a negative 
control. After incubation, 100 µL of Trypan blue was added to quench extracellular 
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fluorescence. Phagocytic activity (number of bacteria internalized per cell) was quantified as 
the MFI of the “positive” cells. 
ROS Production Assay. ROS was assessed in MO/DC in response to no stimuli and 
to a variety of stimulants, including opsonized non-fluorescent E. Coli as a phagocytic 
stimulus, N-formyl-methionine-leucine-phenylalanine (fMLP) as a physiologic peptide, 
phorbol myristate acetate (PMA) a synthetic ester, and PBS as a control (no stimulus; 
baseline measurement). Following a 10 minute exposure to the stimulus, non-fluorescent 
dihydrorhodamine (DHR) 123 (Orpegen Pharma, San Diego, CA) was added to the samples 
as a fluorogenic substrate, which, following intracellular oxidation was converted to 
fluorescent rhodamine (R) 123. MFI of R 123 fluorescence served as a quantitative measure 
of intracellular oxidative activity. 
 
Results 
 
 The mean with SD functional activity of MO/DC from blood, Kupffer cells, and 
splenic macrophages in Sprague-Dawley rats is presented in Figure 14. Samples were run in 
triplicate and there is minimal variability among the matrix and functional test used. For 
Kupffer cells and splenic macrophages, samples were pooled and then run in triplicate. For 
blood, 3 rats were sacrificed and assays were run in triplicate from each animal. When 
measuring the production of ROS with and without stimulants, Kupffer cells had the highest 
level of activity, followed by splenic macrophages and then blood MO/DC. When comparing 
the function of Kupffer cells to the other matrices, they were 31-, 61-, 22-, and 3-fold greater 
than MO/DC when looking at ROS production without stimulant, E. Coli stimulant, fMLP 
stimulant, and PMA stimulant, respectively. The function of Kupffer cells were also 3-, 6-, 3-
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, and 1.6-fold greater than that of splenic macrophages for the tests of ROS production 
without stimulant, E. Coli stimulant, fMLP stimulant, and PMA stimulant, respectively. For 
phagocytosis, this trend was not observed. The matrix with the greatest amount of 
phagocytosis was circulating MO/DC from whole blood. When comparing  between matrices 
with the liver once again serving as the reference, the Kupffer cells had 0.67- and 6-fold the 
phagocytic activity compared with MO/DC and splenic macrophages. 
 Next, we evaluated the contributions of splenic macrophages and blood MO/DC to 
the MPS in wild-type mice (C57BL/6), shown in Figure 15. Once again, the tissue 
macrophages had a greater production of ROS with and without stimulants as compared to 
blood MO/DC. Splenic macrophages produced 11-, 15-, 10-, and 3-fold greater the ROS as 
blood MO/DC without stimulant, with E. Coli, fMLP, and PMA stimulants, respectively. 
Similar to the rat samples, the phagocytosis of blood MO/DC from mice was greater than 
tissue phagocytosis. Splenic macrophages displayed 0.2-fold the activity of blood MO/DC.  
 The function of blood MO/DC in mouse KO models was assessed and compared to 
the C57BL/6 wild-type mice evaluated previously, as shown in Figure 16. Phagocytosis by 
MO/DC in the wild-type mice was 1.9- and 2.3-fold higher than of MO/DC in CCL2 and 
CCR2 KOs, respectively. The CCL5 KOs displayed nearly an identical amount of 
phagocytosis as the wild-type mice, with 1.1-fold the activity in MO/DC. A similar trend was 
seen with the production of ROS in MO/DC, with CCL2 and CCR5 KOs representing a 
fraction of the activity observed in wild-type mice, and the CCL5 KOs displaying equal or 
greater activity than that of wild-type mice. For ROS production (without stimulant), as 
compared to wild-type, CCL2, CCL5, and CCR2 KOs were 0.8-, 2.8-, and 0.6-fold, 
respectively the function. For ROS production after stimulation with E. Coli, CCL2, CCL5, 
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and CCR2 KOs were 0.8, 5.7, and 0.9, respectively times the activity of wild-type mice. ROS 
production after stimulation with fMLP yielded 0.8, 4.6, and 0.8 times the activity of wild-
type mice in CCL2, CCL5, and CCR2 KOs, respectively. Lastly, ROS production after 
stimulation with PMA resulted in 0.6, 1.7, and 1.1 times the activity of wild-type in CCL2, 
CCL5, and CCR2 KOs, respectively.  
 The functional activity of MO/DC from blood and Kupffer cells in beagle dogs is 
presented in Figure 17. Figure 17 represents measurement of MPS activity from a liver 
section and a whole blood sample, drawn from the same animal on the same day. Variability 
in the MO/DC signal arises from performing the tests in triplicate on the same whole blood 
matrix from the Beagle dog. Figure 18 shows the function of MO/DC from three different 
Beagle dogs as measured on a separate day. The signals are comparable between all Beagle 
dogs, indicating that the tests are repeatable and reliable. Once again, it was observed that in 
terms of phagocytosis, the MO/DC circulating in blood are much more phagocytic than  
Kupffer cells in the liver. Additionally, the production of ROS is at least equal or much 
greater in the tissue macrophages than the circulating MO/DC. The MO/DC were 4.5-fold 
more phagocytic than Kupffer cells, and conversely, for the production of ROS, they were 
0.2, 1.2, 0.3, and 0.2 times the activity of Kupffer cells.  
 The last species to be evaluated was pigs. The functional activity of pig blood 
MO/DC is shown in Figure 19. Only blood samples were able to be collected, but this data 
can be used to compare to the activity in blood of other species, as shown in Figure 20. 
Patient data from Chapter 4 was added to this figure. The phagocytic activity in Beagle dogs 
is much greater than that of mice and rats and nearly equal to patients.  
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Discussion 
 
 We observed a consistent difference between the functional activity of tissue 
macrophages and blood MO/DC across species. The phagocytic capacity of blood MO/DC 
was greater than that of splenic macrophages and Kupffer cells in all species. Conversely, the 
production of ROS with or without stimulants in tissue macrophages was at least equal to or 
greater than blood MO/DC. We have also observed a difference in the functional activity of 
MPS cells across species.  
The results obtained were different than what we had hypothesized. We have been 
operating under the assumption that using the matrix of blood in patients was serving as a 
surrogate of the MPS activity in other MPS organs, such as the liver and spleen. The trends 
we observed were consistent across species and we can propose a few reasons as to why we 
have obtained these current results in animal models and how they relate to our prior data in 
preclinical models and in patients. It is important to keep in mind that the results of these 
experiments were obtained in vitro, which may differ entirely from the in vivo environment 
or measurements of function. Assays performed on MO/DC were carried out in whole blood, 
their normal environment, whereas Kupffer cells and splenic macrophages were removed and 
cultured in vitro. It is possible that their function would be much greater within their 
respective tissues. The term functional tests will be used synonymously with probes 
throughout the discussion.  
CCL2 and CCL5 promote the migration and maturation of monocytes and dendritic 
cells, respectively, however, they also have an influence on several other immune cells (130). 
β-chemokines exert an effect on lymphocytes, basophils, eosinophils and mast cells (130). 
Therefore, many of these cell types might be downregulated in both function and quantity in 
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the KO model. Although the probes measured only monocyte activity, it is difficult to 
distinguish how greatly the monocytes were affected in the KO compared with the wild-type 
model, especially compared to the other cell types. The KO models might not represent a 
drastic difference in MO quantity or function as compared to the wild-type model. It is not 
known, but the KO model could affect the granulocytes more so than the MO.  
 When looking at KOs of CCL5 and CCL2 and their receptors (CCL2 and CCR2, 
respectively) we hypothesized less function across all models compared to the wild-type. 
This trend was generally observed in the CCL2 and CCR2 KOs for all probes, with either 
less or relatively equal activity compared with wild-type. For the CCL5 KOs, however, there 
was higher activity in all probes as compared with wild-type. We may have observed the 
trends we expected in CCL2 KOs due to their effect on MO, the key cell involved in NP 
uptake and CL. CCL5 exerts its effect on DC which also may play a role in NP uptake and 
CL (and are gated with MO in our analyses), however, their contributions are minimal 
compared to MO. DC accounts for <1% of circulating leukocytes on the histogram, with MO 
accounting for approximately 5%. DC are primarily antigen presenting cells and messengers 
between the innate and adaptive immune systems. They do not behave like classic 
MO/macrophages of the innate immune system. Knowing the differential consequences of 
CCL5 and CCL2 on immune cell recruitment and activation, we might not expect the CCL5 
KO to have as drastic of an effect on MPS function as compared to a wild-type or CCL2 KO.  
A further explanation for our results could be the fact that there is no true MPS-KO 
mouse model available. The CCL5 and CCL2 KOs can represent a partial KO or 
downregulated MPS in animal models. These KOs however, can also accurately convey a 
tumorigenic environment. There is a growing body of literature that demonstrates that 
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genetic polymorphisms in both the CCL5 and CCL2 genes are significantly associated with 
disease states, including cancer (135, 136). The development of cancers, including gastric, 
hepatocellular, lung, colorectal, vulvar, and ovarian might be due to pro-inflammatory 
environments resulting from CCCL5-403 G/A (rs 2107538) and CCL2 2518 G/A (rs 
1024611) single nucleotide polymorphisms (SNPs) (135). In our studies, we looked at the 
function of blood MO/DC at a single time point, but it appears that the model used might 
indeed be highly translatable to cancer patients.  
One factor that is not taken into consideration for our study is cell age. Monocytes 
represent 3-7% of cells in the bloodstream, and generally within 2 days will emigrate to 
tissues where they mature to fixed macrophages (137). Monocytes within the bloodstream 
give rise to macrophages and DC that can also remain within circulation (137). Mature MOs 
constitute 5-10% of peripheral blood cells (137). These cells have been demonstrated to be 
quite heterogeneous, with varying degrees of granularity and nuclear morphology (137). At 
the extremes, the variation of these mature MOs can be mistaken for granulocytes, 
lymphocytes, natural killer cells and DCs (137). In our studies, we consistently gate on a MO 
population based on SSC vs. FSC but the age of the cell is not taken into consideration. 
Generally the more mature monocytes or macrophages would be expected to display a higher 
functional activity. This was shown with the production of ROS in tissue macrophages being 
higher than that observed in blood MO. However, the reason why the blood MO displayed 
more phagocytosis than the tissue macrophages is unclear. Perhaps the blood MO were 
actually very mature monocytes or contained a large DC population. Alternatively, the 
phagocytosis probe might be most appropriate for the matrix of whole blood. The ability to 
phagocytize or form a phagolysosome might have been destroyed in the tissue macrophages 
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during homogenization (in the case of splenic macrophages). Additionally, our perfusion 
methods to isolate KC from liver sections serve the purpose of isolating an abundance of a 
pure cell colony, however there is no data to show the preservation of cell function post-
isolation.  
Conclusions 
If these probes are a surrogate measure of NP CL or the strength of a NP-MO/DC 
interaction, then dogs would appear to clear the NP quite rapidly, at a much faster rate than 
mice or rats. We have suggested in Chapter 3 that Beagle dogs might not be the appropriate 
or best animal model to use for NP PK and TK studies. Perhaps it is due to the dog’s very 
functionally active MO/DC that NPs do not reach a predicted exposure or AUC based on the 
dose they are administered. It could be due to the rapid CL of particles from the systemic 
circulation of dogs that results in a greater number of dose escalations needed in human 
clinical phase I studies.   
This rationale is compelling, however it is refuted by the fact that MO/DC from dogs 
display comparable activity to MO/DC from patients across all probes. If phenotypic probes 
were the sole tie to NP CL and AUC, then a similar finding between the dog and patient 
models would likely result in comparable MTD-finding study outcomes in terms of dose 
levels and patients enrolled. The findings from this chapter demonstrate that functional 
activity of macrophages and MO/DC represents only 1 component of a very complex system 
that dictates NP PK and PD variability. Dogs specifically have nearly identical MO/DC 
functional activity compared to patients, but they have different NP PK and as a result 
different PD. 
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Figure Legends 
 
 
1. Figure 14.  The function of MO/DC from blood (blue), Kupffer cells (red; liver), and 
splenic macrophages (green) in 3 Sprague-Dawley rats. The amount of phagocytosis 
and the production of reactive oxygen species (ROS) with and without the stimulants 
E. Coli, fMLP, and PMA was measured in the 3 matrices using flow cytometry and 
reported as mean fluorescence intensity (MFI). MO/DC from blood were the most 
phagocytic matrix tested and Kupffer cells were the greatest producer of ROS.  
 
2. Figure 15. The function of MO/DC from blood (blue) and splenic macrophages (red) 
in 3 C57BL/6 mice. The amount of phagocytosis and the production of reactive 
oxygen species (ROS) with and without the stimulants E. Coli, fMLP, and PMA was 
measured in the 2 matrices using flow cytometry and reported as mean fluorescence 
intensity (MFI). MO/DC from blood were the most phagocytic matrix tested and 
splenic macrophages were the greatest producer of ROS.  
 
3. Figure 16. The function of MO/DC from blood in RANTES (CCL5) and MCP-1 
(CCL2, CCR2) gene and/or receptor knockouts compared with C57BL/6 wild-type 
mice. The amount of phagocytosis in the CCL2 and CCR2 KO mice decreased as 
compared with wild-type mice and the production of reactive oxygen species (ROS) 
with and without the stimulants E. Coli, fMLP, and PMA was equal to or slightly 
decreased in the KO vs. wild-type mice.  The CCL5 KO mice displayed higher levels 
of activity across all probes. Cellular function was measured using flow cytometry 
and reported as mean fluorescence intensity (MFI).  
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4. Figure 17. The function of MO/DC from blood (blue) and Kupffer cells (red) in 3 
Beagle dogs. The amount of phagocytosis and the production of reactive oxygen 
species (ROS) with and without the stimulants E. Coli, fMLP, and PMA was 
measured in the 2 matrices using flow cytometry and reported as mean fluorescence 
intensity (MFI). MO/DC from blood were the most phagocytic matrix tested and 
Kupffer cells were the greatest producer of ROS. 
 
5. Figure 18. The function of MO/DC from blood in 3 Beagle dogs, presented as 
phagocytosis (red), ROS production (green), ROS production stimulated by E. Coli 
(purple), ROS production stimulated by fMLP (cyan), and ROS production stimulated 
with PMA (orange). Functional activity was measured using flow cytometry and 
results are reported as mean fluorescence intensity (MFI). The pattern of activity is 
comparable to that of pigs, as seen in Figure 19, with phagocytosis representing the 
strongest signal, ROS production without stimulant and ROS production stimulated 
by fMLP contributing minimally, and ROS production stimulated with E. Coli and 
PMA contributing moderately. Also in a similar fashion to pigs, ROS production 
stimulated with PMA was the most variable signal.  
 
6. Figure 19. The function of MO/DC from blood in 3 pigs, presented as phagocytosis 
(red), ROS production (green), ROS production stimulated by E. Coli (purple), ROS 
production stimulated by fMLP (cyan), and ROS production stimulated with PMA 
(orange). Functional activity was measured using flow cytometry and results are 
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reported as mean fluorescence intensity (MFI). The pattern of activity is comparable 
to that of Beagle dogs, as seen in Figure 18, with phagocytosis representing the 
strongest signal, ROS production without stimulant and ROS production stimulated 
by fMLP contributing minimally, and ROS production stimulated with E. Coli and 
PMA contributing moderately. Also in a similar fashion to pigs, ROS production 
stimulated with PMA was the most variable signal. 
 
7. Figure 20. The function of MO/DC from the blood of preclinical and clinical species. 
Data is presented by groups of species, as C57BL/6 mice (blue), Sprague-Dawley rats 
(red), Beagle dogs (green), pigs (purple), and patients (cyan).  Phagocytosis and ROS 
production with and without the stimulants E. Coli, fMLP, and PMA were measured 
using flow cytometry and results are reported as mean fluorescence intensity (MFI). 
The activity of Beagle dogs and patients was comparable across all probes, and the 
strongest activity observed among all species. Mice consistently had the lowest level 
of activity.  
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Figure 14. Sprague-Dawley Rat MPS Function in Blood, Liver, and Spleen 
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Figure 15. Wild-type Mouse MPS Function in Blood and Spleen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
 108 
Figure 16. MPS Function in Wild-type Mice Compared With CCL2, CCL5, and CCR2 
KO Mice  
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Figure 17. Beagle Dog MPS Function in Blood and Liver 
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Figure 18. Beagle Dog MO/DC Function in Blood 
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Figure 19. Pig MO/DC Function in Blood 
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Figure 20. Variability in MPS Function Among Preclinical Models 
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CHAPTER VI 
 
DEVELOPMENT OF A HIGH-THROUGHPUT SCREENING SYSTEM TO TEST 
THE INTERACTION OF NANOPARTICLES WITH THE MONONUCLEAR 
PHAGOCYTE SYSTEM 
 
Introduction 
 
 In patients, it was observed that our phenotypic probes were correlated with the CL of 
the NP PLD (Chapter 4). We sought to determine whether a similar relationship existed 
between other NP platforms and cellular function. Measuring the strength of the interaction 
between NPs and the MPS may indicate whether the NP undergoes a higher or lower 
clearance rate or extent by MPS or produces toxicity to the MPS in animal models and 
patients. This information could be extremely valuable early on within the drug development 
process. A novel ex vivo screening platform was developed to evaluate the interaction 
between NPs and the MPS.   
 Historical data from our lab as well as the literature has shown that nanoparticles are 
cleared through the mononuclear phagocyte system (MPS), and it is the carrier, not the active 
drug, that dictates interaction with the MPS and its subsequent clearance by the MPS. We 
demonstrated this phenomenon in a series of in vitro experiments. Using flow cytometry and 
darkfield microscopy, we showed dose-dependent incorporation of PLD in monocytes. This 
work was based on earlier experiments conducted by Zucker, et al. which showed 
incorporation of titanium dioxide nanoparticles into ARPE-19 cells (138).  
In our studies, Mono Mac 6 cells were incubated with PBS, PLD at 10, 50, or 100 
µg/mL or doxorubicin (small molecule) at 10, 50, or 100 µg/mL. Figure 21 shows A) 
MonoMac6 cells incubated with PLD particles at 10 µg/mL and B) Mono Mac 6 cells 
incubated with non-liposomal free doxoroubicin at 10 µg/mL. The nucleus of the cells has 
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been stained red and there is a faint white border that represents the cytoplasm. The free 
doxorubicin particles (Figure 21B) are for the most part not contained within cell boundaries 
and appear to be associated with the cell surface. The white halos, all of which are contained 
within the boundaries of the plasma cytoplasm, represent PLD particles. The particles all 
appear to be within the boundaries of the cytoplasm, which would suggest that they are 
mostly internal. The cells visualized with darkfield microscopy were in suspension and this 
same sample was then run on a BD FACS Canto flow cytometer. Figure 22 shows the 
quantities of particles internalized within the Mono Mac 6 cells as a dose-dependent function. 
Uptake was measured via changes in FL-2 (PE) fluorescence. This part of the experiment 
suggests that uptake of PLD particles into monocytes reaches a dose-dependent saturation. 
  To conduct this study, we sought to add the same number of particles across agents 
to the screening platform. As the number of NPs interacting with MPS cells may change the 
response, we wanted to avoid this one source of variability by providing uniformity in 
particle exposure. Therefore, the first step taken in these experiments was particle 
quantification. Next, we developed methods for running 100 µL matrix samples in a high-
throughput screening (HTS) mode using flow cytometry.  
 
Methods 
Particle Quantification 
 Transmission Electron Microscopy (TEM): Starting with the dilutions used for the 
NTA analysis, 20 µL of nanoparticle drug solution was pipetted onto parafilm. Depending on 
the density of the particles obtained in the TEM image, it was sometimes necessary to further 
dilute the stock solutions. A microscopic coated grid for TEM was carefully placed on top of 
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the drop of drug solution (shiny surface comes into direct contact with the droplet). The grid 
was left atop the solution for 3 minutes before carefully wiping off the solution by blotting 
once with a Kimwipe. The particles on the grid were stained with 20 µL of 2% uranyl acetate 
for 10 seconds. Three TEM images from different fields of each grid were recorded. 
Additionally, 3 grids were made per final drug solution (after proper dilutions). The 
magnification of the image captured and used for particle counting was recorded. Back 
calculations were required to determine the number (concentration) of particles in an 
assumed homogenous set volume (1 mL) stock solution.  
The particles that were characterized by all three methodologies and run through the 
HTS platform are listed in Table 13 along with their particle classifications.  
High-throughput Screening (HTS) via Flow Cytometry: Flow cytometry was 
performed using a BD LSR-II flow cytometer equipped with a high throughput system (HTS) 
sample loader for 96-well plates and running FACSDiva v. 6.1 software.  Analysis of flow 
cytometry files was performed using FlowJo version 7.1 software.   
Whole blood was collected in sodium heparinized (green top) collection tubes from 
human healthy volunteers (HVs) or SCID mice and left at room temperature. Blood samples 
of six HVs were assessed and the blood of 30 SCID mice was pooled. As there are many NPs 
to evaluate, running all samples for 1 donor generally takes 3 consecutive days of sample 
processing. On a particular day of experimenting, separate 2-mL deep well polypropylene 
processing plates were used for phagocytosis and ROS assays. The phagocytosis plate was 
used for phagocytosis positive (+), blood only, and blood and drug (no test) samples. The 
ROS plate was used to measure all ROS with and without stimulants. 100 µL of whole blood 
was pipetted into each 2 mL deep well to be used within the plate. 10 µL of the respective NP 
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if applicable was added to the appropriate well. The 10 µL of NP added was of the diluted 
NP solution calculated from the TEM counting studies. Processing plates were vortexed 
carefully and placed in an incubator at 37°C and 5% CO2 on an incubator rocker, left 
powered at the highest setting (10) for 1 hour.  
Following the 1 hour incubation, the functional assays were completed as described 
previously in Chapter IV. After the last centrifugation and vacuum aspiration step, 300 µL of 
RPMI was added to each sample. Using a multi-channel pipette, 200 µL from each deep well 
was put into a standard round- bottom 96-well plate that was put on the HTS attachment for 
the BD LSR II flow cytometer.  
Statistics. To test the visible differences in MPS-HTS data between males and 
females, a Wilcoxon rank sum test, the non-parametric equivalent to the t-test was used.   
Results 
 The major result of the HTS experiments is that we have developed an effective 
system that offers a new methodology for analyzing the interaction between nanoparticles 
and the MPS in an ex vivo platform. For the first time ever, we have employed flow 
cytometry in a high-throughput screening (HTS) platform to assess the interaction between 
nanoparticles and cells. In the following sections we report on the pilot data obtained from 
the system.  
MPS-HTS Using Blood Samples from Mice. Nanoparticles in Table 13 were 
incubated in whole blood obtained from SCID mice and run through the HTS system. The 
results of these experiments are presented in Figure 23. For phagocytosis, the highest signal 
received was in blood (with no drug added). Adding nanoparticles diminished the phagocytic 
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capacity of blood MO/DC, although there was variability in this response across NP. When 
the polymeric surfactant and microemulsion particles were added, phagocytosis was 
relatively preserved as compared with the control (no drug) sample. This might indicate that 
these types of particles interact with MPS cells differently.  
 In general, when measuring the production of ROS with and without stimulants, there 
was an increase in the production of ROS after exposure to the nanoparticle. This was 
particularly evident with a conjugate, polymeric surfactant, and small molecule doxorubicin, 
in which the production of ROS increased, especially when stimulated with PMA.  
A few NPs did not cause a strong phenotype in any of the markers that were 
measured. A Non-PEGylated liposome, PLGA, and polymer of 5FU were associated with 
low levels of phagocytosis and production of ROS. Therefore, these particles may have been 
internalized to inhibit further phagocytosis of opsonized E. Coli particles, but they did not 
cause an oxidative stress that resulted in the production of ROS.  
Running Blood Samples from Healthy Human Volunteers Through the HTS 
System. Nanoparticles in Table 13 were also incubated in whole blood obtained from 6 
human healthy volunteers (3 males, 3 females) and run through the HTS system. The results 
of these experiments are presented in Figure 24. In contrast to the data observed in SCID 
mice, the level of phagocytosis by human blood MO/DC generally increased or remained 
unchanged after the addition of nanoparticles.  Phagocytosis increased in samples incubated 
with a PEGylated liposome + doxorubicin, PEGylated liposome (empty), polymer surfactant 
(with and without doxorubicin), non-PEGylated liposome, microemulsion (with and without 
paclitaxel), and a conjugate. There was no change between the drug-free control sample and 
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PLGA or polymer of 5FU in terms of phagocytosis. There was no positive phagocytosis 
signal observed from the sample incubated with SM doxorubicin.   
 In general, when measuring the production of ROS with and without stimulants, there 
was an increase in the production of ROS after exposure to the nanoparticle. This increase 
was more evident in males vs. females, which is detailed in the next section. The increase 
was not observed with doxorubicin, which caused a low and similar signal across all ROS 
measures. In general, the nanoparticles polymer surfactant and non-PEGylated liposome, 
elevated ROS across all stimulants when compared to control. The microemulsion with or 
without paclitaxel, PLGA, conjugate, and polymer of 5FU, caused an elevation in the 
production of ROS when stimulated with PMA but did not necessarily increase ROS across 
the other stimulants. We evaluated the change in signal between no drug and drug, and for 
some functional tests, such as ROS production stimulated with E.Coli, there was little change 
from no drug, as seen in Figure 25. 
 Intra and Inter-person Variability. We noticed that the data from the HTS 
experiments did not produce substantial intraperson variability. In fact, the samples from 
each volunteer in triplicate were nearly identical. This certainly ensures the reproducibility of 
this technology. We did observe, however, considerable interperson variability. As 
highlighted in previous chapters, particularly Chapter I, the MPS is a complex system with 
many factors causing it to behave differently across individuals. The reasons for these 
difference are unclear, and they might be elucidated in a larger dataset.  
Correlation Between SCID Mouse Phenotype and Mouse and Human PK. The 
last step of these experiments was to see if the phenotypic data obtained from SCID mice 
correlated with PK observed in mice and in patients. There were four nanoparticles for which 
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we had HTS phenotypic data and in vivo PK data from mice and three nanoparticles for 
which we had the complete data set for humans. For mice, those NPs were PLGA, non-
PEGylated liposome, PEGylated liposome, and polymeric surfactant + doxorubicin. For 
patients, the NPs were non-PEGylated liposome, PEGylated liposome, and polymeric 
surfactant + doxorubicin. As these data sets are quite small, we show the rate of particle CL 
and functional activity (MFI) for each agent on 2 y-axes and observe that the greater the 
particle CL, the greater functional activity of MO/DC in the blood sample. This is shown in 
Figure 26 for A) mice and B) patients when measuring phagocytosis and Figure 27 for A) 
mice and B) patients when measuring the production of ROS.  
 
Discussion 
 The goal of these experiments was to see if a system could be designed that could 
evaluate the interactions of many different NPs in blood. MO/DC, key cells of the MPS were 
used as a surrogate for drug-cell interactions within the MPS as a whole. We wanted to 
profile the baseline function of cells and what happens to these cells once they encounter a 
NP. Through this work that we have developed methods that do indeed measure cellular 
function with and without the presence of a NP in a high-throughput mode. We have taken 
experiments that if performed using standard flow cytometry would take approximately 40 
hours to complete between sample processing and running the FCM and brought the 
experiment down to 8 hours total. In these 8 hours we can collect 100 data points. This is an 
impressive amount of data to collect, and as more NPs are obtained and evaluated using the 
HTS system, we will develop an extensive library.  
	  
	  
 120 
The ultimate goal of having this library or data bank, is to ascertain what specific NP 
platforms do to cells. We can postulate based on the composition, size, and structure of the 
NP, their likelihood for interacting with the MPS. We can run new compounds through the 
system and see where they ranked compared to other NPs, especially those that are approved 
and used clinically due to their efficacy and low toxicity profile.  
On the basis of these results we are left with two different theories about the direct 
effects of NPs on MO/DC in terms of phagocytosis. In mice, adding NPs decreased 
phagocytosis and in humans, adding NPs increased phagocytosis. Since the 2 species 
contradict each other it is difficult to determine which theory holds true. The first theory is 
that the uptake of particles causes saturation within the cell and therefore, the phagocytosis of 
E. Coli particles would decrease as compared to the control sample. Conversely, there is a 
theory that the particles serve as a phagocytosis “primer” in that they stimulate the cells to 
take up additional molecules, such as E. Coli. For this theory, the nanoparticles that are 
suspected to react with the MPS strongest would cause the greatest amount of phagocytosis. 
Unfortunately, we cannot tell which phenomenon truly occurs with our conflicting data, but 
we could postulate that the latter theory applies in human samples. 
It is important to note that one reason for the difference observed in murine and 
human blood samples could be due to the different cell proportions between the species. 
Human blood is largely made up of granulocytes, but there are up to 10% 
monocytes/dendritic cells. Murine blood is predominantly lymphocytes and approximately 
5% are monocytes/dendritic cells. Our phenotypic probes test positive in both granulocytes 
and monocytes. Therefore, the human samples have two large cell populations competing for 
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particle uptake. It is possible that this influences the resultant data and causes a different MFI 
to be reported as compared with murine samples.  
The increased ROS production makes sense as the NPs may stress cellular redox 
systems.  In mice, there were three distinct classes of particles that caused an increase in 
ROS. This indicates that cytotoxic small molecules, like doxorubicin, conjugates and 
polymeric surfactants might cause the most toxicity in blood cells. In human samples, nearly 
all particles caused an elevation in ROS production. The highest increases were once again 
seen in conjugates and also in microemulsions. In both species, liposome based platforms 
appeared to cause minimal ROS production. This is interesting in that only liposomes have 
been manufactured commercially and administered to patients on a large scale. 
Another observation made from collecting this data was the existence of interperson 
variability but lack of intraperson variability. The absence of intraperson variability was very 
encouraging. The fact that our system can measure the same value in three samples that are 
from the same matrix but are processed separately indicates that our findings are real and not 
artifact. The existence of interperson variability should not be entirely surprising based on 
our historical data. We have demonstrated that the MPS is highly variable in patients, with 
factors such as age, gender, body composition, and hormones all exerting an effect. Even in 
the 6 volunteers we used for this study, differences in their MPS could be cause for the 
variability seen in the data. When looking at various aspects that could influence the 
variability in the 6 HVs, gender seemed to be the most significant contributor. Females 
seemed to have higher phagocytosis and males higher ROS production. While it is hard to 
make inferences from this small data set, this could indicate a general health difference 
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between the two groups of individuals that we tested. Alternatively, the observed gender 
differences might be due to hormonal influences, nutritional or other factors. 
 
Conclusions 
We observed strong correlations between phenotype and NP PK in terms of CL 
within both human and SCID mouse blood. This data is encouraging as it provides a second 
potential use for this system in the drug development process. Not only can the system now 
provide information indicating the strength of drug and MPS interaction, but it can now also 
potentially have predictive value when designing human PK studies based on preclinical 
data.   
This system can be an extremely valuable tool in the drug development process, as it 
could indicate very early on in development whether the candidate is worthwhile to pursue. 
Once we have evaluated enough compounds, we will hopefully be able to quantify 
thresholds. That is, if a drug causes a signal of a certain high value, it should not be used as a 
chemotherapeutic. Perhaps it interacts with the MPS too extensively and therefore would be 
cleared too rapidly from the body. However, this high interaction could be advantageous for 
the development of an immunotherapeutic. A low interaction or value below the threshold 
might serve as an early indicator of a worthwhile chemotherapeutic drug. A minimal MPS 
interaction will lead to longer NP circulation times and a greater likelihood that the drug 
eventually reaches the target.  
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Table 13. List of Nanoparticles and Their Classifications that were Characterized by 
NTA, DLS, and TEM and run through the HTS System 
 
Particle Number Particle Type 
1 
 
PEGylated liposome containing doxorubicin 
2 Empty PEGylated liposome 
 
3 Non-PEGylated liposome containing 
daunorubicin 
 
4 
 
Polymeric surfactant (no active drug) 
5 Polymeric surfactant containing doxorubicin 
 
6 Microemulsion (no active drug) 
 
7 Microemulsion containing paclitaxel 
 
8  
 
Polymer of 5FU 
9 Conjugate (no active drug) 
 
10 
 
PLGA rod shaped particle (no active drug) 
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Figure Legends 
 
Figure 21.  The uptake of nanoparticles in a cell line, Mono Mac 6 as imaged by darkfield 
microscopy A) MonoMac6 cells incubated with PLD particles at 10 µg/mL and B) Mono 
Mac 6 cells incubated with doxoroubicin at µg/mL. The nucleus of the cells has been stained 
red and there is a faint white border that represents the plasma membrane. The white halos 
represent PLD particles. This data shows that nanoparticles are taken up into monocytes and 
to a much greater extent than free doxorubicin. This data also confirms the findings in Figure 
22, that the particles associated with cells via flow cytometry were indeed internalized. 
 
Figure 22. Incorporation of PLD into monocytes occurs in a dose-dependent fashion. 1 mL 
Mono Mac 6 cell suspensions were incubated with PBS or PLD at 10, 50, or 100 µg/mL and 
the sample was run on a BD FACS Canto flow cytometer. Shifts in FL-2 (PE) indicate an 
increase in cellular PLD, which has an excitation/emission spectrum captured within this 
fluorophore channel.  
 
Figure  23. Phagocytosis and the production of ROS with and without the addition of 
nanoparticles in pooled female SCID mouse blood measured through the HTS system. 
Phagocytosis decreased from baseline after the addition of nanoparticles, whereas ROS 
increased or stayed the same. Different particle types cause a varying degree of functional 
activity.  
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Figure 24. Phagocytosis and the production of ROS with and without the addition of 
nanoparticles in 6 healthy human volunteer blood samples measured through the HTS 
system. Phagocytosis and ROS both increased from baseline after the addition of 
nanoparticles. Different particle types cause a varying degree of functional activity.  
 
Figure 25.  The change in the production of ROS (stimulated with E. Coli) in human healthy 
volunteer blood samples with the addition of various nanoparticles compared to no addition 
of a nanoparticle. In general, the production of ROS with E. Coli stimulation  decreased from 
not adding a nanoparticle (whole blood only) to  adding a nanoparticle platform.  
 
Figure 26. The rate of nanoparticle clearance (Striped bars) was proportional with the level 
of phagocytosis (MFI; solid bars) in in A) SCID mouse and B) patient blood samples. There 
are four nanoparticles, non-PEGylated liposome, PEGylated liposome, and polymeric 
surfactant + doxorubicin, (+ PLGA for mice) for which there is a data set of both HTS 
functional activity and in vivo PK data. This trend will be assessed further when additional 
nanoparticles become available.  
 
Figure 27.  The rate of nanoparticle clearance (Striped bars) was proportional with the level 
of ROS production (MFI; solid bars) in A) SCID mouse and B) patient blood samples. There 
are four nanoparticles, non-PEGylated liposome, PEGylated liposome, and polymeric 
surfactant + doxorubicin, (+ PLGA for mice) for which there is a data set of both HTS 
functional activity and in vivo PK data. This trend will be assessed further when additional 
nanoparticles become available.  
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Figure 21. The Uptake of PLD or Free Doxorubicin in Mono Mac 6 Cells Incubated at 
10 µg/mL 
 
A) 
 
PEGylated liposomal doxorubicin 
 
B) 
 
Free doxorubicin 
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Figure 22. Dose-dependent uptake of PLD in Mono Mac 6 Cells 
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Figure 23. Nanoparticles Tested in a Female SCID Mouse Blood Sample Using the HTS 
System 
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Figure 24. Nanoparticles Tested in Human Healthy Volunteer Blood Samples Using the 
HTS System  
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Figure 25. The Change in ROS Production (stimulated with E. Coli) After Adding 
Nanoparticles Compared with No Drug Added Using the HTS System 
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Figure 26. Nanoparticle Clearance Increases Proportionately with the Level of 
Phagocytosis in (A) SCID mice and (B) Patients 
A 
 
B 
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Figure 27. Nanoparticle Clearance Increases Proportionately with the Level of ROS 
Production in (A) SCID mice and (B) Patients 
A 
 
 
 
B 
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CHAPTER VII 
DISCUSSION AND PERSPECTIVE 
 
 
This work has added greatly to our understanding of the unique clinical 
pharmacology associated with nanoparticle anticancer agents. The primary biologic focus 
was to measure the function of circulating MPS cells in the blood and tissue resident MPS 
cells known to play a role in the clearance of nanoparticles. In this work, we profiled the 
behavior of nanoparticles in preclinical and clinical systems using a retro-translational 
approach. We began our work in the clinic, by studying patients receiving a nanoparticle 
anticancer agent. We then validated some of the clinical findings in animal models, where we 
could evaluate tissues and a variety of nanoparticles that would not be accessible in or 
available to humans. Lastly, we took the findings of the clinical and preclinical systems and 
sought to develop an ex vivo screening system that could potentially provide valuable 
information in the nanoparticle drug development processs.  
In Aim 1, we determined that the function of monocytes and dendritic cells, as 
measured by phagocytosis and the production of reactive oxygen species (ROS) could serve 
as a phenotypic probe in patients. A phenotypic probe is a test that can be administered to a 
patient as a potential indicator of a drug’s pharmacokinetics and pharmacodynamics, which 
can then be used to individualize therapy. This work used patients with recurrent epithelial 
ovarian cancer receiving the nanoparticle PEGylated liposomal doxorubicin (PLD; Doxil) as 
part of their standard of care. We demonstrate an association between cell function and the 
clearance of PLD for both phagocytosis (R2= 0.43, P= 0.04) and production of ROS (R2= 
0.61, P= 0.008). This result supports our hypothesis and is an encouraging finding for 
patients in light of the high variability seen with nanoparticle agent pharmacokinetics and 
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pharmacodynamics. Additionally, we have shown that our phenotypic probes can be used to 
predict PD endpoints such as progression free survival. In the 10 patients enrolled on the 
study thus far, we show that the level of MO/DC phagocytosis corresponds to how quickly a 
patient’s disease will progress.  
Next, in Aim 2, we evaluated the function of MO/DC in blood and compared this to 
the function seen in tissue macrophages, such as Kupffer cells and splenic macrophages. We 
studied a variety of species, including mice, rats, dogs, and pigs. For mice, we evaluated both 
wild-type and MPS-deficient/KO models. We were not able to confirm our hypothesis that 
the cellular function of tissue macrophages (liver and spleen) in preclinical models and their 
interaction with NPs will be comparable to the function and particle uptake of circulating 
MO/DC in the blood. For all species, the phagocytosis of blood MO/DC was much greater 
than the phagocytosis of tissues macrophages. The tissue macrophages generated more ROS 
than blood MO/DC. This finding highlights the importance of in vivo studies. The blood 
matrix is complex and contains many factors (complement, proteins, clotting factors, etc.) 
that might play a role in NP uptake and delivery. This is the natural matrix that the NP 
encounters when administered to humans, and culturing cells from tissues might not 
adequately mimic the actual tissue environment within humans for our in vitro/ex vivo NP 
studies. Additional, in vivo, studies on particle uptake are needed to examine NP uptake by 
tissue macrophages in situ. 
Another component to Aim 2 were the allometric scaling models and the NP clinical 
phase I outcome studies. Our findings support our hypothesis that these types of evaluations 
would elucidate an appropriate animal model to be used in NP PK and toxicology testing. We 
found that dogs are not the proper model to use for testing NP PK. The use of dogs for this 
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purpose was first introduced in the allometric models, in which dogs were consistently the 
fastest clearers of NPs across all species, including humans. This finding was supported by 
our follow up study which evaluated phase I clinical data. When NP first in man doses were 
based off of preclinical dog models, the number of dose escalations, length of study, and 
patients enrolled to complete the phase I study were significantly greater than what is seen 
with typical small molecule agents. These findings are of great importance as they could 
ultimately lead to a reduction in healthcare costs and less harm to patients. 
Lastly, in Aim 3, we profiled the interaction between nanoparticle agents and the 
MPS via an ex vivo high throughput screening (HTS) platform. We were able to successfully 
develop methods that allowed us to characterize and profile the interaction of NP agents with 
the MPS in blood samples from human volunteers and SCD mice. We ran 10 compounds 
through our screening system and this information may ultimately be used to optimize the 
drug development of NP agents for the treatment of cancer and other diseases. We consider 
this data collection to be the start of a library or database which we can continue to add to by 
screening additional NPs.  We believe that once many compounds are added, we can support 
our hypothesis that when there is a low interaction between NPs and the MPS, the agent 
could likely be used as a chemotherapy agent, and conversely, when there is a strong 
interaction, it could serve as a potential immunotherapy/vaccine. In our work so far, we have 
already shown differences in blood MO/DC with and without the addition of a NP agent. We 
see the most significant differences between male and female healthy volunteers, where 
females have greater phagocytosis after NP exposure and males have greater ROS production 
after NP exposure.  
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There are many potential projects and future directions that this work may lead to. 
Most notably, a larger clinical study comparing phenotypic probe guided dosing versus 
conventional BSA dosing could indicate whether our studies can provide more accurate dose 
predictions and whether this then leads to better outcomes in terms of efficacy and safety for 
patients. 
Another area that could be investigated is the creation and design of probe substrates.  
In these studies, opsonized, fluorescent E. Coli served as the probe substrate for 
phagocytosis, however the average E. Coli molecule is 0.5 µm x 2 µm, making them much 
larger than standard 100 nm nanoparticles. To truly mimic nanoparticle phagocytosis, it 
would be best to use a molecule that closely resembles nanoparticles. E. coli also possess 
different surface properties which make them susceptible to opsonization by various blood 
components such as complement, immunoglobulin and pathogen-associated molecular 
patterns (PAMPS), thus facilitating receptor-mediated phagocytosis. Therefore, construction 
of empty PEGylated liposomes (in the case of a Doxil/PLD mimic) loaded with a fluorescent 
dye such as FITC would be incredibly useful and informative as a probe. This type of probe 
could be a better reflection of particle uptake and subsequent clearance from the systemic 
circulation.  
Next, we can build further on Aim 2. We have a large body of data demonstrating that 
dogs are probably not the best model for NP PK studies. However, we have noted that the 
activity of MO/DC in blood is nearly identical between dogs and patients. Since the 2 species 
have markedly different PK and PD and their phenotypic probe activities are identical, there 
is some other major biological factor(s) contributing to the difference. An exploratory 
analysis that attempts to discover and examine factors underlying these differences could 
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further strengthen our argument that other animal models need to be considered in NP drug 
development.  
Additionally, we can add to the findings from the HTS development. We can add 
additional healthy volunteers to determine whether true gender differences do indeed exist, 
and then of course explore what specifically is driving the difference between the groups. 
Now that the methods have been established, we can continue to screen NPs that become 
available through university or industry collaborators. We can provide information to the NP 
developer in terms of where their compound ranks among others in MPS-interaction level, 
particularly those that are commercially available or have demonstrated success in patients.  
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APPENDIX I 
Methods 
Dedrick Plot Methods. Another approach to allometric scaling are the species 
invariant time methods (1). As time goes on, and an animal increases in size, their heart and 
respiratory rate decrease (1,2). However, when looking at these parameters on a 
physiological time scale, animals will have, regardless of their size difference, the same 
number of heart beats and breaths in their lifetime (1). The first to describe how to apply the 
concept of species invariant time was Dedrick et al., when they looked at methotrexate 
disposition in 5 different mammalian species following IV administration (3). Dedrick’s 
transformation of chronological time to physiological time, is now referred to as the Dedrick 
Time Equivalent Model, where the Y-axis is normalized by dividing plasma concentrations 
by dose (mg/kg) and body weight W (kg), and 0.25 represents a constant for the conversion 
from chronological to physiological time on the X-axis.  
When Dedrick employed this method, plasma concentrations of methotrexate in the 
species he chose to study were superimposable, indicating that raw concentration versus time 
data from preclinical models could be scaled in order to predict disposition in humans. Later, 
Boxenbaum further developed the concept of the Time Equivalent Model by introducing two 
new units of pharmacokinetic time (4, 5). Kallynochrons and apolysichrons are transformed 
time units of the Elementary and Complex Dedrick Plots, respectively. Noting the numerical 
value of 0.25 to be somewhat empirical, Boxenbaum showed that the exponent could be 
derived from the allometric relationship of clearance (5).  
 Assuming monoexponential kinetics, the elimination rate constant (k) equals: 
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k = CL/V = (a/b)Bx-y    (1) 
 The plasma concentration (C) following an intravenous bolus dose (D) is equal to:  
C = (D/V)e-kt – (D/bBy)e-(a/b)(Bx-y)t  (2) 
 Equation 10 can then be rearranged, so that when y =1 interspecies superimposability 
will occur when the plasma concentration is divided by dose per unit body weight and is 
plotted as a function of time divided by B1-x [2]. 
__C__ = (1/b)e-(a/b)(t/B1-x)    (3) 
(D/B) 
 
 The slope of this Naperian log-linear plot will be equal to (-a/b) and the intercept will 
be equal to (1/b) (2). This plot, termed as The Elementary Dedrick Plot, so as not to be 
confused by other Dedrick plots to follow, which are more complicated allometric coordinate 
adjustments, is expressed as: 
Y-axis = Concentration   (4) 
     Dose/W 
 
X-axis = Time     (5) 
    W1-b 
Where b is the exponent of clearance. 
 In this plot, one unit of PK time is equal to B1-x units of chronological time. The unit 
of pharmacokinetic time is known as a kallynochron. In an Elementary Dedrick Plot, 
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interspecies superimposability cannot occur unless y =1(2). If y does not equal 1, then both 
the intercept and slope will be species dependent (2). A kallynochron will indicate whether 
clearances can be compared among species (2). The time unit can be interpreted as: for one 
mouse kallynochron, dog kallynochron, and human kallynochron, each species will have 
cleared the same volume of drug per kilogram of body weight (2). The superimposability 
among species will depend on whether y = 1, or V is directly proportional to the species body 
weight (2). If data is not superimposable, one may conclude that the model cannot be used to 
scale clearance of the agent across species (2). 
 Apolysichrons are the PK time units of the Complex Dedrick Plot (1). This unit is 
developed on the basis of V not being directly proportional to body weight, or where y does 
not equal 1(2). Here, concentration is divided by dose per body weight and plotted against 
time divided by By-x.  
__C__ = (1/b)e-(a/b)(t/By-x)    (6) 
 (D/B) 
 
 Here, the apolysichron time unit equals t/By-x. In one apolysichron, each species will 
eliminate the same fraction of the drug in the body (2). In one kallynochron, each species 
clears the same volume of blood or plasma per kilogram of body weight (2). An apolysichron 
is also the chronological time needed by species to clear the same volume of blood or plasma 
per (kg)y units of body weight (2). Therefore, the kallynochron derives significance from 
clearance, whereas apolysichrons represents a species-independent measure of turnover time, 
half-life, and mean residence time (MRT). The Complex Dedrick Plot is expressed as (1): 
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Y-axis = Concentration   (7) 
     Dose/Wc 
 
X-axis = Time     (8) 
    Wc-b 
 
Where b and c are exponents of clearance and volume, respectively.  
 
Results 
 
 Standard Allometric Scaling. Using the standard allometric equation, the MPS-
associated variables were assessed as variables for correlation. Liver weight, spleen weight, 
kidney weight and liver blood flow can be found in Appendix Figure 1A-D. Allometric 
scaling using the Maximum Life-Span Potential (MLP) Method for CL is presented in 
Appendix Figure 2 A-G.  R2 values for these methods are summarized within Appendix 
Table 1. As would be expected, a relationship was observed when CL was multiplied by the 
MLP in hours of a mouse, rat, or dog and plotted against their body weight. As CL was 
highly correlated with body weight and MPS-associated variables previously, adding MLP 
improved the observed trend. This was particularly noticeable for SPI-077, the agent with the 
lowest correlation using standard allometric scaling. The correlation for SPI-077 improved 
by an average of 0.05.  
 Species Invariant Time Models. Appendix Figure 3 A-C depicts the Dedrick Time 
Equivalent scaled models for S-CKD602, Doxil®, and SPI-077, respectively. The 
concentration versus time profiles of the three PEGylated liposomes did not converge among 
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species when scaling in this manner. The lack of superimposability was also seen when 
substituting liver weight, spleen weight, and total monocyte count for body weight (data not 
shown). One trend that was observed in the Time Equivalent Model was that after 
normalizing both axes on the concentration versus time profile, dogs had the fastest clearance 
and consequently the lowest exposure (AUC) for all three agents.  
 Complex Dedrick Plots for S-CKD602, Doxil®, and SPI-077 are shown in Apendix 
Figure 4 A-C. The use of liver weight, spleen weight, or total monocyte count did not 
improve the fit of the data when compared to body weight (data not shown). 
The Elementary Dedrick Plot scaled models for S-CKD602, Doxil®, and SPI-077 are 
shown in Appendix Figure 5 A-C.  There was no superimposability among any of the 
species or between a single species and humans, for any of the PEGylated liposomes. The 
same lack of superimposability was seen in the Complex Dedrick Plot, the Elementary 
Dedrick and, Time Equivalent models when normalizing by a physiological variable other 
than body weight (data not shown).  
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Table 1. Summary of average (SD) R2 regression values, coefficients, and exponents using 
the MLP Method 
 
 
 
 
 
 
   S-
CKD602 
    Doxil     SPI-077   
 R2  coefficient exponent R2  coefficient exponent R2  coefficient exponent 
                   
Body 
Weight 
(kg) 
0.978 
(7.41E-3)   
2.82E+5 
(6.51E+4) 
1.29 
(0.119)          
0.987 
(8.99E-
3) 
0.995 
(0.499) 
0.958 
(0.337) 
0.892 
(0.0313) 
0.0973 
(0.0425)   
1.69 
(0.0812) 
                    
Spleen 
Weight 
(kg) 
0.969 
(0.0201) 
2.12E+8 
(1.87E+8)     
1.16 
(0.0891)          
0.799 
(0.032)        
1.08E+8 
(4.67E+7)   
1.06 
(0.0698)  
0.799 
(0.032)        
1.08E+8 
(4.67E+7)   
1.69 
(0.0729) 
                    
Liver 
Weight 
(kg) 
0.926 
(0.0242) 
3.17E+7 
(1.83E+7) 
1.44 
(0.0976) 
0.892 
(0.0424)  
7.5E+6 
(2.59E+6) 
1.43 
(0.28)    
0.812 
(0.0278)   
5.17E+6  
(1.6E+6)  
2.03 
(0.0781) 
                    
Kidney 
Weight 
(kg) 
0.972 
(0.0249) 
1.38E+8 
(1.4E+8)  
1.28 
(0.113)       
0.97 
(0.0129)   
2.17E+7 
(4.08E+6) 
1.15 
(0.0814)     
0.825 
(0.0305) 
5.33E+7 
(1.75E+7) 
1.88 
(0.0794) 
                    
Spleen 
Blood 
Flow 
(mL/min) 
0.993 
(0.0105) 
7.84E+4 
(2.56E+4) 
1.47 
(0.099)    
0.991 
(6.96E-
3)  
4.40E+4 
(1.08E+4) 
1.37 
(0.0855)     
0.877 
(0.0268) 
1970 (998)   2.27 
(0.0929) 
                         
Liver 
Blood 
Flow 
(mL/min) 
0.995 
(2.21E-3) 
1020 
(173)   
1.53 
(0.105)          
0.998 
(2.09E-
3)  
703 (326)   1.43 
(0.0868)  
0.901 
(0.0247) 
1.92 (1.64)    2.4 
(0.0975) 
                                    
Total 
Monocyte 
Count 
0.92 
(0.0245)   
0.42 
(0.257) 
0.871 
(0.0653) 
0.951 
(7.46E-
3) 
0.523 
(0.449)  
0.809 
(0.0493)  
0.95 
(0.0171)  
3.07E-6 
(3.51E-6) 
1.42 
(0.0544) 
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Figure Legends 
 
1. Comparison of S-CKD602, Doxil, and SPI-077 clearance [from left to right] in mice, 
rats, dogs, and humans by allometric scaling of A) liver weight, B) spleen weight, C) 
kidney weight, and D) liver blood flow. Human data is included in allometric graphs to 
demonstrate the general behavior of liposomes across all species, however human data 
was not included in the regression which was used to predict behavior of liposomal PK in 
humans from preclinical species.   
 
2. Comparison of S-CKD602, Doxil, and SPI-077 clearance [from left to right] in mice, 
rats, dogs, and humans by allometric scaling using the Maximum Lifespan Potential 
Method (MLP) for A) body weight, B) spleen weight, C) liver weight, D) kidney weight, 
E) liver blood flow, F) spleen blood flow, and G) total monocyte count. 
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Appendix Figure 1. 
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Appendix Figure 2.  
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Appendix Figure 3. 
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Appendix Figure 4. 
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Appendix Figure 5. 
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